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Abstract
Diabetic retinopathy (DR) is the result of microvascular changes in the retina
due to hyperglycemia which alter the blood-retinal barrier (BRB). The increased
permeability of BRB results in the accumulation of extracellular fluid, the
development of diabetic macular edema (DME) and capillary occlusion. Capillary
occlusion results in retinal ischemia which increases vascular endothelial growth
factor (VEGF) levels, increases vascular permeability and results in
neovascularization in proliferative diabetic retinopathy (PDR) patients. The
treatments clinically used for DR are panretinal photocoagulation (PRP) for PDR and
injectable vascular endothelial growth factor inhibitors (anti-VEGFs) for DME.
The safety of PRP and anti-VEGF therapy on the retina and optic nerve was
evaluated in treatment-naïve DR patients by undergoing structural (OCT, HRT) and
functional (visual field, visual acuity) diagnostic tests over a two year time period.
Streptozotocin (STZ)-induced diabetic rats received different doses of intravitreal
anti-VEGF injections to analyze the safety of VEGF inhibition on neuronal cells.
Retinal cell cultures were exposed to different doses of anti-VEGF to assess
metabolic activity, function and toxicity by colorimetric assays.
This study found that patients treated with PRP, despite showing an
improvement in peripheral perfusion, had a significant and progressive decline in
peripheral vision. There was a discrepancy between the grading of the optic nerves
post-PRP by ophthalmologists despite the absence of significant morphological
changes. Anti-VEGF treatment was found to be potentially detrimental to the optic

nerve by decreasing retinal nerve fiber layer thickness, increasing cup/disk ratio and
cup volume over time. STZ-induced diabetic rats receiving intravitreal anti-VEGF
injections had a dose-dependent increase in retinal ganglion cell death. Results from
retinal cell cultures suggest that anti-VEGF treatment may be detrimental to the
retina by decreasing cellular metabolic activity, and increasing cytotoxicity of retinal
cells. Overall, PRP was relatively safe and improved peripheral perfusion but
resulted in misdiagnosis of glaucoma based on non-morphological colouration
changes of the optic nerve post-PRP. Anti-VEGF treatment appeared to be
detrimental to the optic nerve by causing damage to retinal cells. In contrast to
current recommendations, it is suggested to monitor both the retina and optic nerve
status in patients undergoing frequent injections.

Keywords
Diabetic retinopathy, retina, optic nerve, panretinal photocoagulation (PRP), pascal,
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Chapter 1

1

Introduction

1.1 Diabetes Mellitus
Diabetes mellitus is a chronic metabolic disorder characterized by
hyperglycemia1. Hyperglycemia is a condition in which glucose plasma levels are
uncharacteristically high and exceed 7 mmol/L. In diabetics, hyperglycemia
results in chronic low grade inflammation induced by inflammatory cytokines,
creating persistent damage to host cells2. This mechanism also drives insulin
resistance and additional complications that are commonly associated with
diabetes. Even though hyperglycemia is a common feature of this disorder, the
etiology of diabetes can vary. Based on underlying causes, diabetes can be
divided into two major categories; type 1 and type 2. Type 1 diabetes (T1DM) is
associated with absolute insulin deficiency due to autoimmune destruction of
pancreatic beta cells that store and release insulin3. T1DM accounts for
approximately 10% of all instances of the disease. These patients require
exogenous insulin delivery by injections or insulin pumps to survive due to the
inability of their pancreas to synthesize insulin.
The specific etiology of type 2 diabetes (T2DM) is unknown, although
autoimmunity is not considered to be a major factor. T2DM accounts for
approximately 80-90% of all cases of diabetes4. T2DM is primarily caused by a
combination of insulin resistance, lack of receptor sensitivity to insulin, and
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insulin deficiency. The pancreatic beta cells are still able to secrete insulin but at
an insufficient level to overcome insulin resistance5. Insulin resistance happens
at sites of adipose tissue, skeletal muscle and the liver4, 6. T2DM patients require
medications which function to increase insulin release and improve insulin
sensitivity to maintain normal blood glucose levels. If hyperglycemia persists and
is not controlled in T2DM patients, over time the pancreas continues to
compensate by making more insulin, resulting in exhaustion of beta cells leading
to functional deterioration, defective insulin secretion and eventual insulin
deficiency (Figure 1.1). At that stage, T2DM patients require an exogenous
insulin supply like T1DM patients7.
There are multiple factors that may contribute to the development of
diabetes. According to clinical data, the risk of T2DM increases with familial
history of diabetes (genetic factors), high blood pressure, ethnicity, metabolic
syndrome, dyslipidemia, hypertension, dietary factors, sedentary lifestyle, obesity
and age (Figure 1.2). T1DM typically occurs in individuals that have familial
history of the disease and in genetically susceptible individuals5, 8.
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Figure 1.1. Pathogenesis of T2DM. Genetic predisposition and lifestyle factors
contribute to insulin resistance. Once resistance develops, to compensate, beta
cell hyperplasia attempts to maintain normal blood glucose levels. Eventually,
beta cell secretory dysfunction sets in, leading to impaired glucose tolerance and
diabetes. Adapted from: Kumar V, Abbas AK, Aster JC, Perkins JA. Robbins
basic pathology. Philadelphia, PA: Elsevier; 2018.
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Figure 1.1 Pathogenesis of T2DM
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Figure 1.2. Risk factors affecting the development of T2DM. Adapted from:
Holt RIG, Cockram CS, Flyvbjerg A, Goldstein BJ. Textbook of diabetes. 4th ed.
Chichester, West Sussex, UK: Wiley Blackwell; 2010.
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Figure 2 Risk factors affecting the development of T2DM
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1.2 Epidemiology
Diabetes has emerged as a major global health problem, with serious
health-related and socioeconomic impacts on individuals and populations alike5.
Diabetes is the fifth leading cause of death worldwide, claiming 4 million
individuals annually. The pandemic growth of the disease is further being driven
by improvements in healthcare which has increased life expectancy, shifted
demographics, socioeconomics, and lifestyle nutritional patterns5. The rates of
diabetes have been rapidly rising in middle- and low-income countries where the
prevalence of obesity in adults and children has been increasing5, 9, 10, 11. In 2010,
the International Diabetes Federation estimated that worldwide, there were 285
million people living with diabetes and that the number would exceed 400 million
in the next twenty years12. In 2014, the World Health Organization ran a global
report on diabetes and concluded that the number of people living with diabetes
had already reached 422 million, far exceeding the predictions made in 2010
(Table 1)11. With the severity of disease complications, co-morbidities and
complexity of therapy, the management of diabetes consumes vast resources
worldwide5.
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Table 1.1. Global prevalence of diabetes.
Prevalence (%)

Number (millions)

WHO Region
1980

2014

1980

2014

3.1

7.1

4

25

5

8.3

18

62

Eastern Mediterranean Region

5.9

13.7

6

43

European Region

5.3

7.3

33

64

South-East Asia Region

4.1

8.6

17

96

Western Pacific Region

4.4

8.4

29

131

Total*

4.7

8.5

108

442

African Region
Region of the Americas

* Totals include non-Member States
Global report on diabetes. World Health Organization, Geneva, 2016.
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1.3 Diabetic Complications
Diabetes can be a debilitating disease that is associated with high
morbidity and mortality rates. The prime characteristic of diabetes is abnormal
glucose metabolism and other metabolic complications that lead to serious
pathological effects that affect practically all body systems4. These complications
vary among individuals afflicted with diabetes primarily due to differences in the
level of glycemic control and underlying pathophysiology5. High blood glucose is
the primary culprit for the initiation of the damage and the continuation of effects
on target tissues and organs13. Hyperglycemia induces oxidative stress through
the excessive conversion of glucose into pyruvate through glycolysis. The
pyruvate is then oxidized in the citric acid cycle to generate high amounts of the
electron donors NADH and FADH2 that feed into the electron transport chain. As
the result, the inner mitochondrial membrane voltage gradient increases until a
threshold is reached, blocking further electron transfer within complex III. The
arrest of electron transport chain being halted leads to coenzyme Q transferring
only a single electron to molecular oxygen, generating superoxide. Increased
production of superoxide results in cellular toxicity through the activation of five
known major pathways involved in diabetic complications: the polyol pathway,
intracellular production of advanced glycation end products, expression of the
receptor for advanced glycation end products and related activating ligands, the
protein kinase C pathway, and the hexosamine pathway14, 15. For most diabetic
patients, complications are associated with macrovascular disease in the
arteries, microangiopathy, the thickening of basement membranes, diabetic
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nephropathy, retinopathy, neuropathy, and other tissues. These complications
are observed in both T1DM and T2DM patients4, 16.
Cardiovascular events are the most common complications that occur in
patients with T1DM and T2DM. They are involved in as many as 80% of all
patient deaths4, 17. The hallmark of this complication is atherosclerosis which is
the narrowing of large and medium-sized arteries by fatty plaques. As mentioned
previously, in diabetic patients, it is the low-grade inflammation that damages
hosts’ cells which leads to endothelial dysfunction, alters the microvasculature,
accelerates atherosclerosis development and leads to heart disease
complications2, 18-20.
Diabetic nephropathy is the leading cause of chronic kidney disease in the
world21. Small amounts of albumin found in the urine, also known as
microalbuminuria, are the earliest manifestations of diabetic nephropathy.
Microalbuminuria, due to glomerular leakiness, is caused by hyperglycemia
damaging the podocytes of the glomerular filtration barrier and increasing
permeability of the capillary wall13, 22. Without treatment, 80% of T1DM and 2040% of T2DM will progress to definite nephropathy over the course of 10-15
years once symptoms appear. By roughly 20 years post-diagnosis, as glomerular
filtration rate progressively decreases, 75% of T1DM and 20% of T2DM afflicted
individuals will develop end-stage renal disease and require dialysis or kidney
transplantation4, 23, 24.
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Diabetic neuropathy may affect the central nervous system, peripheral
sensorimotor nerves, and autonomic nervous system. Most commonly the
disorder affects the lower extremities, disrupting both motor and sensory
functions. Over time, the effects may spread to the upper extremities as well.
Diabetic neuropathy may also affect the autonomic nervous system, resulting in
bladder and bowel dysfunction, erectile dysfunction, sudden foot drop, wrist drop
or cranial nerve palsy4, 25. Diabetic patients tend to be more susceptible to skin
infections compared to healthy individuals. Infections of the lower extremities
may develop into gangrene and bacteremia. Such infections result in 5% of all
diabetic deaths4, 26-28.
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1.4 Diabetic Retinopathy
1.4.1 Retinal Anatomy
The retina is a layered structure consisting of photoreceptors and nerve
cells lining the inner part of the eye29. The inner layer of retina is in contact with
the vitreous body, a gel like substance that fills the space between retina and the
lens, and the outer layer is associated with the choroid, a layer of highly
vascularized connective tissues (Figure 1.3). The retina is not uniformly thick,
normally being 0.55 mm at the macula and roughly 0.1 mm at the fovea, the
latter being the centre of the macula17. The blood is supplied to the retina through
two different sources. The central retinal artery supplies blood to the inner twothirds of the retina while the vascular choroid and its choriocapillaris, located
posterior to the retina, supply blood to the outer third.
The macula is located near the centre of the retina approximately 4 mm to
the temporal side of the optic disk and measures approximately 4 mm in
diameter (Figure 1.4). Roughly 1.5 mm in diameter, the fovea is responsible for
our central vision and is located in the centre of the macula. It is composed
entirely of cone photoreceptors which are responsible for our sharp visual acuity
and colour vision. Within the fovea is a 0.5 mm diameter foveal avascular zone
(FAZ) which is supplied nutrients through the diffusion of blood from the
capillaries of the underlying choroid5. As a result, there is a depression at the site
where FAZ is located which functions to prevent any dispersion or loss of light
signal30.
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Figure 1.3. Sagittal section of the eye. Internal structure of the eye by
OpenStax College [CC BY 3.0 (http://creativecommons.org/licenses/ by/ 3.0)], via
Wikimedia Commons.
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Figure 3 Sagittal section of the eye

15

Figure 1.4. Wide-field photograph of the normal human fundus.
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Figure 4 Wide-field photograph of the normal human fundus
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The optic nerve is located 3 mm to the medial side of the macula and is
known as the blind spot since there are no retinal layers in this zone31. Ganglion
cell axons from the neuronal cell layer, located near the inner surface of the
retina, puncture through the sclera to form the optic nerve which transmits visual
information to the brain. The optic nerve head is roughly 1.8 mm in diameter.
Visually, the rim of the optic nerve is known as the disk and it contains nerve
fibers from the ganglion cells. The inner section of the rim is the edge of the more
whitish coloured cup which does not contain nerve fibers32.
The retina is composed of a “three-neuron system” consisting of
photoreceptors, first-, and second-order neurons. In terms of location, inner
refers to the layer of cells closest to the vitreous. Outer refers to the layers of
cells closest to the sclera, the white outer coat of the eye. Retinal cell nuclei are
arranged in specific bands called nuclear layers (Figure 1.5). The outer nuclear
layer (ONL) is composed of photoreceptor nuclei and lies closest to the vascular
choroid and sclera33. The human eye contains two types of photoreceptors, the
rods and cones. Rods sense contrast, brightness and motion while cones are
responsible for fine resolution, spatial resolution and colour vision.
Photoreceptors absorb light and initiate neuro-electrical impulses. The density of
cones increases as you approach the macula, with the fovea having exclusively
cones while the periphery of the retina is primarily rod-dominated31.
The inner nuclear layer (INL) of the retina is composed of the nuclei of the
first-order neurons, the bipolar cells. INL also contains the nuclei of amacrine,
horizontal and Muller cells which modulate activity of the ganglion cells31.
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Figure 1.5. Histology of the retina. (A) Schematic diagram showing the
arrangement of the different cell types in the retina. (B) Hematoxylin and eosin
stained primate retina demonstrating the layered arrangement of the retina.
Image by OpenStax College [CC BY 3.0 (http://creativecommons.org/licenses/by/
3.0)], via Wikimedia Commons.
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Figure 5 Histology of the retina
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Bipolar cells are the dominant cells, with horizontal cell nuclei being found in the
outer parts and the amacrine cells found in the inner parts of the INL. Muller cell
nuclei are uniformly distributed throughout the INL. Functionally, bipolar cells
transmit signals from photoreceptor cells found below the inner layer of the INL to
ganglion cells located above the upper layer of INL. Bipolar dendrites synapse
with photoreceptors and horizontal cells, while their axons synapse with ganglion
and amacrine cells31. Horizontal cells have a role in retinal processing and
release inhibitory neurotransmitters, primarily GABA, that act on photoreceptor
cells. Amacrine cells mostly play an inhibitory role and modulate signals that
reach ganglion cells. Amacrine cells may be GABAergic and dopaminergic or can
release acetylcholine31.
The innermost nuclear layer of the retina is referred to as the ganglion cell
layer (GCL) which houses the nuclei of the second-order neurons, the retinal
ganglion cells31. The GCL is located near the inner surface of the retina between
the nerve fiber layer and the inner plexiform layer31. The GCL varies in thickness,
being the thickest near the fovea and thinnest at the periphery of the retina33. The
axons of the ganglion cells form the nerve fiber layer which is located at the
innermost surface of the retina. The bundles of the nerve fibers form the optic
nerve which is responsible for transmitting visual information to the brain31.
The dense networks of axons and dendrites found in the retina are located
within the outer plexiform layer (OPL), located between ONL and INL, and the
inner plexiform layer (IPL), located between INL and GCL. The axons of
photoreceptors which form synaptic terminals with bipolar cells and horizontal
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cells are contained within the OPL. Meanwhile, IPL contains axons of bipolar and
amacrine cells, and dendrites of ganglion cells31. Glial, astrocytes and
oligodendrocytes are located in the GCL and IPL layers of the retina33. The
combination of the neural processing from all of the layers transmits visual
information to the brain through the optic nerve31.
The blood-retinal barrier (BRB) is comprised of two parts: the endothelial
cells of the retinal blood vessels which are connected by tight junctions and the
outer retinal pigment epithelial (RPE) cells. The microenvironment of the retina is
regulated by BRB which is essential for the structural and functional aspects of
the retina34. Under normal conditions, BRB controls molecular and fluid
movements between the retina and choroidal vasculature, preventing leakage
and other harmful agents from entering the retina. The inner BRB (iBRB) is
formed by tight junctions between retinal endothelial cells resting on a basal
lamina (Figure 1.6)35. They are covered by the processes of astrocytes and
Muller cells36. Pericytes are separated from the endothelial cells by the basal
lamina and all three cell types play a critical role in maintaining the proper
functioning of BRB34. The tight junctions between RPE cells form the outer BRB
(oBRB)37. The barrier separates the neural layer of the retina from the
choriocapillaris, maintains the cohesion of the neural layer of the retina, facilitates
phagocytosis of rods and cones, and transports nutrients from the blood to the
outer retina31, 34. In addition, RPE improves image resolution by absorbing light
and preventing light from scattering31.
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Figure 1.6. Blood-retinal barrier under normal conditions. The inner BRB is
formed by tight junctions between retinal endothelial cells which are covered by
the processes of astrocytes and Muller cells. The tight junctions between RPE
cells form the outer BRB (oBRB). Image from: Kaur C, Foulds W, Ling E. Blood–
retinal barrier in hypoxic ischaemic conditions: Basic concepts, clinical features
and management. Prog Retin Eye Res 2008;27(6):622-647.
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Figure 6
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Pericytes, cells that are embedded within the basement membrane of the
capillary blood vessels, have numerous roles within the retina (Figure 1.7). The
ratio of pericytes to endothelial cells is 1:1; more than any other vascular bed38.
Pericytes function to regulate vascular tone, support the capillary walls, secrete
extracellular material such as fibronectin and are capable of phagocytosis38, 39.
Actin, myosin and tropomyosin are all expressed in pericytes, making them
capable of contraction and assist in regulation of blood flow within the retinal
microcirculation39, 40, 41. Pericytes have also been shown to inhibit proliferation of
endothelial cells and angiogenesis42.
Muller cells are the supporting glial cells of the retina that are similar in
function to oligodrendocytes31. Muller cells have an important role in maintaining
BRB by supporting neuronal activity, facilitating uptake of nutrients, disposing of
wastes, maintaining ion homeostasis, controlling signaling molecules and
maintaining extracellular pH43, 43, 45, 46. Muller cells under normal conditions have
been found to reduce vascular permeability by secreting pigment epithelium
derived growth factor (PEDF). The primary function of PEDF is to antagonize the
actions of vascular endothelial growth factor (VEGF) which increases the
permeability of BRB.
Astrocytes function to maintain the integrity of retinal vessels and are
located in the nerve fiber layer, GCL, IPL and outer INL31, 47, 48, 49. Astrocytes
have been shown to modify the morphology of the retinal vascular endothelium
by increasing the expression of tight junction protein ZO-1, thus increasing the
barrier properties50.
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Figure 1.7. Schematic of the retinal capillary. An inner layer of retinal
endothelial cells is enclosed by a tube of basement membrane, which in turn is
surrounded by pericytes. Image from: Holt RIG, Cockram CS, Flyvbjerg A,
Goldstein BJ. Textbook of diabetes. 4th ed. Chichester, West Sussex, UK: Wiley
Blackwell; 2010.

26

Figure 7 Schematic of retinal capillary
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1.4.2 Epidemiology
DR is the leading cause of blindness amongst working age (20-74 years
old) adults with DME being the most common cause of this vision loss16, 51.
Approximately 50% of patients with DR will develop DME16. Presently, millions of
people are living with undiagnosed diabetes, and the incidence of T2DM in
developed countries is on the rise; even as medicine advances, diabetes remains
a major public health concern27, 52, 53. Duration of diabetes is a significant risk
factor for developing DR, which is a vascular complication of both T1DM and
T2DM26. After 15 years, 90% of T1DM patients develop some form of retinopathy,
with half of them progressing to PDR which is characterized by retinal
neovascularization16, 27. Retinopathy may be the first clinical manifestation of
T2DM in some patients16. According to the United Kingdom Prospective Diabetes
Study, approximately 37% of individuals who were first diagnosed with T2DM
patients had already developed retinopathy. Within 15 years of developing
diabetes, 60% of patients with T2DM develop some form of retinopathy26.
Following the 15 year period, 5-10% of T2DM patients will develop PDR and 1015% will develop DME. T2DM patients develop much earlier diabetic eye disease
compared to T1DM patients as the majority of these patients live with
undiagnosed diabetes and start treatment or lifestyle changes very late. Patients
that have high-risk PDR, within 5 years have a 60% risk of developing severe
vision loss and a 30% risk of moderate vision loss from DME26. Blindness occurs
due to DR complications such as vitreous hemorrhages or traction retinal
detachments16.
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1.4.3 Pathogenesis
The exact pathogenesis of DR remains unknown, however, the underlying
cause of its development is hyperglycemia17. This is supported by clinical
observations of diabetic patients, the duration of their disease relative to the
development of DR, retinopathy development in hyperglycemic animal models,
and epidemiological and clinical trials showing a strong correlation between
glycaemia control and retinopathy development17, 53-58. The exact mechanism by
which hyperglycemia leads to retinopathy is unknown16. The initiation and
progression of DR is very complex and relies on several factors that are not yet
understood. These factors vary depending on the different stages of DR and the
uniqueness of individuals16. Glucose has a vital role in the disease as it enters
the retina by facilitated diffusion, hence a constant high serum glucose will result
in high levels of glucose in the retina27. Multiple theories have been proposed on
the potential mechanisms that facilitate retinal damage, specifically BRB, as a
result of high glucose concentrations in the retina but none of them have been
sufficiently supported. The theories propose that high blood glucose levels initiate
several biochemical changes and processes, such as aldose reductase
converting excess glucose into sorbitol16. Sorbitol is unable to diffuse out of the
retina and, thus, accumulates resulting in damage27, 59. Another theory suggests
that high glucose concentrations result in the glycosylation of proteins that play a
key role in cellular dysfunction, such as selectively activing the β-isoform of
protein kinase C60, 61.
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What is absolutely known is that hypoxia, or oxygen deficiency, plays a
major role in the breakdown of BRB in a diabetic eye and is present early in the
development of DR17, 62. The pathology developing in the microvascular retinal
capillaries is responsible for the breakdown of BRB. The first and most wellrecognized pathologic feature of BRB is the loss of pericytes with thickening of
the capillary basement membrane and microaneurysm development (Figure
1.8)34, 63, 64.
During the early stages of DR development, there is a thickening of the
capillary basement membrane. Hyperglycemia is directly related to the abnormal
production of constituents of the basement membrane, such as fibronectin or
collagen, and accumulation of advanced glycation end products. These thicken
the basement membrane, increase vascular dysfunction and may possibly
occlude retinal capillaries65. Rat studies have shown that thickening of the
capillary basement membrane may be prevented with aldose reductase
inhibitors, but the results have not been consistent and have shown no effect on
preventing the progression of DR according to a clinical trial17, 66, 67, 68. The loss of
pericytes through apoptosis appears to be initiated by high blood glucose levels.
Pericyte loss may potentially have an impact on the formation of
microaneurysms34, 69, 70.
Due to capillary closure, oxygen delivery becomes increasingly limited in a
diabetic eye, leading to retinal hypoxia. In addition, reduced oxygen delivery is
further exacerbated by the higher amounts of glycated hemoglobin in diabetic
patients’ red blood cells34. Hemoglobin, when exposed to plasma glucose
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Figure 1.8. Pathologic features of BRB breakdown in a diabetic eye. (A)
Basement membrane thickening (arrow) in the retinal arteriole. Periodic acidSchiff stain, magnification x250. Image from: Holt RIG, Cockram CS, Flyvbjerg A,
Goldstein BJ. Textbook of diabetes. 4th ed. Chichester, West Sussex, UK: Wiley
Blackwell; 2010. (B) Diabetic microaneurysms, trypsin retinal digestion. (C)
Normal retinal capillaries, trypsin retinal digestion. Normal retinal capillaries are
composed of approximately equal numbers of endothelial cells and pericytes.
The nuclei of the endothelial cells are elongated while the pericytes have small,
dark nuclei. The pericytes are embedded in the basement membrane of the
capillary wall. (D) Retinal capillaries in diabetes mellitus, trypsin retinal digestion.
A preferential loss of pericytes occurs in the early stages of diabetic retinopathy,
disturbing the normal 1:1 ratio between pericytes and endothelial cells. Arrows
denote pericyte ghosts in the capillary basement membrane. Diabetic thickening
of the basement membrane causes intense staining with PAS stain. Images
from: Eagle RC. Eye pathology an atlas and text. Philadelphia (Pennsylvania):
Wolters Kluwer; Lippincott Williams & Wilkins; 2011.
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Figure 8 Pathologic feature of BRB breakdown in a diabetic eye

A
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through non-enzymatic glycation pathways, forms glycated hemoglobin71. Nondiabetic patients produce normal levels of glycated hemoglobin. In diabetic
patients, if the normal blood glucose levels are not maintained and become
elevated, the concentration of glycated hemoglobin increases. The lifespan of the
glycated hemoglobin is approximately 3 months which allows it to be used as an
approximation of average glucose levels over the last 3 months in diabetic
patients. Glycated hemoglobin has a high affinity for oxygen, relative to normal
hemoglobin, resulting in decreased oxygen delivery to the retina and contributing
to hypoxia34. In an attempt to compensate for oxygen loss, the body increases
blood flow to the retina and blood hemoglobin concentrations.
During the early stages of DR, there is vasodilation of blood vessels within
the retina due to a combination of hyperglycemia and hypoxia which may further
contribute to the breakdown of BRB34, 72. During the later stages, retinal hypoxia
is further enhanced by decreased capillary circulation. The reduced circulation is
caused by many factors. As the basement membrane thickens, the bore of the
vessels affected is reduced, impeding blood flow34. Blood flow is also restricted
by abnormal plasma viscosity due to increased levels of fibrinogen in diabetic
patients and hemoglobin aggregation34, 73, 74, 75. Previous studies have shown that
patients with diabetic retinopathy have abnormal blood viscosity. This increased
plasma viscosity is due to elevated levels of fibrinogen and α-2-macroglobulin34.
Compared to non-diabetic patients, patients with DR have increased red blood
cell aggregation. Plasma viscosity, platelet and red blood cell function, vessel
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wall structure, permeability and auto regulatory mechanisms all contribute
towards the progression and severity of DR17.
Capillary closure results in a severe reduction of blood flow to the retina
and increased leukocyte adherence to the capillary endothelium34, 76. The
resulting tissue hypoxia results in up-regulation of adhesion molecules ICAM-1
and VCAM-1 which are involved in leukocyte adherence69, 77, 78, 79. The
aggregation of red blood cells may also be involved in capillary closure80. The
occlusion of capillaries further drives retinal hypoxia and the up-regulation of
vascular permeability and angiogenic factors81. VEGF and nitric oxide are
especially important in increased permeability and vascular dilation of BRB,
control of free radicals, inflammatory mediation and hemodynamic alterations
which all play a role in the disruption of BRB integrity. Hydrogen peroxide, which
is produced from the phagocytosis of retinal components, disrupts tight junctions
and causes dysfunction of BRB. Reactive oxygen species, also, indirectly
increase vascular permeability of retinal blood vessels by increasing VEGF gene
expression in endothelial cells34, 82, 83.
VEGF is an angiogenic growth factor that plays a central role in retinal
neovascularization and vascular permeability which results in the development of
macular edema27, 34, 84, 85. The development of ischemia in the retina creates
hypoxia resulting in increased levels of hypoxia-inducible factor 1 (HIF-1) and
increased levels of genes containing HIF-1 binding site in the promoter region,
including VEGF27. VEGF is expressed by a wide range of cells including
astrocytes, RPE, pericytes, amacrine, Muller and endothelial cells86. The exact
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mechanism by which VEGF increases vascular permeability is unknown. VEGF
binds to VEGFR1 (Flt-1) and VEGFR2 (KDR/Flk-1), both of which are tyrosine
kinase receptors and are known to regulate angiogenesis87. Activation of the
receptors results in disruption of tight junctions of retinal endothelial cells by
decreasing the expression of occludin which is important in tight junction stability
and barrier function. As a result, the permeability of BRB increases leading to
BRB breakdown in DR88. The activity of VEGF may be responsible for developing
fenestrations in endothelial cells which further increases vascular permeability89,
90, 91

. VEGF may also cause rearrangement of inter-endothelial junction-

associated proteins such as VE-cadherin and tight junction proteins including
ZO-134, 92, 93. By creating inter-endothelial gaps, endothelial cleavage, and
degenerative changes in endothelial basement membranes that affect the
structural integrity of the microvessels, VEGF leads to the extravasation of
albumin and blood plasma proteins34, 84, 94. According to Starling’s Law which
describes the relationship between stroke volume and end diastolic volume, the
end result of the process is edema formation. Edema is the term used to
describe an accumulation of fluid in tissues. The increased permeability, induced
by VEGF, leads to osmotically active molecules leaking out into the surrounding
tissue followed by water loss. The hydrostatic pressure in the capillaries and
vessels increases the flux of water from the vessels to the tissue and results in
edema formation95.
By increasing permeability, VEGF has also been shown to control
inflammatory responses34, 85, 96. As a result of VEGF’s pro-inflammatory actions,
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ICAM-1 and VCAM-1 expression is increased on the surface of vascular
endothelial cells, augmenting the attachment of leukocytes to vascular walls34, 78,
97, 98

. The adherence of leukocytes to the vascular endothelium breaks down

BRB, further increasing vascular permeability, retinal edema and loss of central
vision by causing apoptosis of endothelial cells and blockage of the capillaries76,
77, 86, 99, 100, 101

. Inhibition of VEGF and ICAM-1 has been shown to decrease the

permeability of BRB34, 102.
The most common manifestation of BRB breakdown is an increase in
retinal volume due to increased permeability and accumulation of extracellular
fluids in the retina. The fluid accumulation occurs most commonly in macula,
creating cystic spaces within and leads to edema. Edema may be spread over an
area if there is widespread BRB breakdown in the peripheral retina, or can be
restricted to focal areas of macular capillaries34.
During angiogenesis, there is an extensive breakdown of BRB32. Pericytes
have been documented to inhibit TGF-β-mediated vascular endothelial cell
proliferation. Loss of pericytes, as mentioned previously, creates a loss of this
inhibitory effect and may stimulate endothelial cell proliferation and
neovascularization33. New vessel formation on the retina breach through the ILM
and proliferate along the interface between the vitreous and the inner surface of
the retina. These new blood vessels, which grow in response to VEGF, are highly
susceptible to bleeding when a posterior vitreous detachment (PVD) occurs and
can result in visual loss due to vitreous hemorrhage27, 34. Furthermore, glial and
RPE cells migrate and surround the neovascularization, forming fibrotic scar
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tissue. If the vitreous and the scar tissue contract, traction on the retina can
occur, resulting in a tractional retinal detachment. If the macula is involved, there
is severe loss of vision which can become permanent unless the retina is
surgically reattached in a timely matter27.
The up-regulation of VEGF has been implicated in the etiology of macular
edema and new vessel formation, as such, it might be expected that both
abnormalities would always be present together. However, clinical data suggests
otherwise. Macular edema can occur in all stages of DR. Additional factors, apart
from the up-regulated VEGF, are likely involved in the etiology of macular edema
and PDR in the diabetic eye34.
A previous study has demonstrated that capillary outgrowth from retinal
explants was significantly increased when the serum of diabetic patients was
added to the media compared to serum from non-diabetic patients. A significantly
greater capillary outgrowth occurred when the serum from PDR subjects was
added to the media, indicating that circulatory factors play a major role in the
development of DR103. Over time, as hyperglycemia continues to alter the
microenvironment of the retina, the retinal structure deteriorates resulting in
vision loss.
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1.4.4 Clinical Features of Diabetic Retinopathy
DR can be broadly classified into non-proliferative diabetic retinopathy
(NPDR), pre-proliferative retinopathy and proliferative retinopathy (PDR)27, 29. It is
crucial that the level of retinopathy is accurately diagnosed and treatment is
administered depending on the specific NPDR level, as there is a risk of
progression to PDR27. Diabetic maculopathy, described as the presence of
macular edema or DME in the macula, can occur at any or all stages of DR.
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1.4.4.1

Non-proliferative diabetic retinopathy

NPDR is the milder form of retinopathy and can be further subdivided into
mild, moderate and severe cases based on the extent of hemorrhages,
microaneurysms, hard exudates and cotton wool spots104. Mild NPDR is marked
by at least one microaneurysm and a low number of hemorrhages26. Retinal
capillary microaneurysms appear as red dots which form as a result of structural
weakness within the capillary wall due to the loss of structurally supportive
pericytes. Microaneurysms may also form from fusion of capillary kinks or
loops105. Other clinical features of NPDR are nerve fibre layer and dot blot retinal
hemorrhages (Figure 1.9A), retinal exudates (Figure 1.9B) and “cotton wool
spots” (Figure 1.9C) which represent localized infarction of the nerve fibre layer.
Retinal hemorrhages can occur either within the retinal substance or
superficially amongst the nerve fiber layer (NFL). When present in the NFL,
retinal hemorrhages tend to form strips of flame-shaped markings (Figure 1.9D).
Retinal exudates are lipid residues from damaged capillaries and are yellow in
appearance. They may be isolated or found in clusters which often form into
circular areas surrounding a cluster of microaneuysms and are referred to as
“circinate patches” (Figure 1.9E). Exudates are the result of increased vascular
permeability allowing fluid and lipoprotein to leak into the surrounding retina. If
exudates occur outside of the macula, no treatment is required. Over time,
exudates may dissipate by themselves.
“Cotton wool spots”, or soft exudates, indicate regions of retinal
ischaemia27, 29. These areas are fluffy and white in appearance representing
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Figure 1.9. Non-proliferative retinopathy. (A) View of the superonasel retina
showing numerous dot-blot intraretinal hemorrhages. This image was originally
published in the Retina Image Bank® website. Henry J. Kaplan and Niloofar Piri.
NPDR. Retina Image Bank. 2013;5345. © the American Society of Retina
Specialists. (B) Exudates in the right macular area. This image was originally
published in the Retina Image Bank® website. Mallika Goyal and Sridhar A.
Exudative Diabetic Maculopathy. Retina Bank. 2013;11894. © the American
Society of Retina Specialists. (C) Cotton wool spots. This image was originally
published in the Retina Image Bank® website. Henry J. Kaplan and Niloofar Piri.
Retinopathy.Retina Bank. 2013;4967. © the American Society of Retina
Specialists. (D) View of elongated lighter red flame hemorrhages and more oval
and darker red blot hemorrhages. Image from: Holt RIG, Cockram CS, Flyvbjerg
A, Goldstein BJ. Textbook of diabetes. 4th ed. Chichester, West Sussex, UK:
Wiley Blackwell; 2010. (E) Photograph of left eye shows circinate (ring pattern)
lipid surrounding a leaking microaneurysm inferonasal to the optic nerve. This
image was originally published in the Retina Image Bank® website. Jeffrey G.
Gross. NPDR with CSME. Retina Bank. 2012;1094. © the American Society of
Retina Specialists. (F) Fluorescein angiography displaying capillary nonperfusion
inferior to the macula. This image was originally published in the Retina Image
Bank® website. Mallika Goyal and Sridhar A. DR Nonperfusion. Retina Bank.
2014;17533. © the American Society of Retina Specialists.
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Figure 9 Non-proliferative diabetic
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microinfarcts developing in the nerve fiber layer of the retina and form from the
accumulation of cytoplasm within the nerve axons or axoplasm. The transport
system is energy-dependent and relies on the integrity of the retinal capillary bed.
If a capillary occlusion occurs and nerve fibers cross the area, transport will fail.
However, axoplasmic transport will continue on either side of the occlusion where
the capillaries remain intact. As a result, there is an accumulation of deposits at
the site of ischemia. An increase in the development and accumulation of cotton
wool spots may be indicative that the retinopathy is developing into a more
serious type104.
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1.4.4.2

Diabetic Macular Edema

Diabetic macular edema (DME) is the most common cause of vision loss
in patients with diabetic retinopathy and can occur at any stage in the overall DR
process26, 27. DME is the leading cause of vision loss because T2DM is more
prevalent than T1DM and maculopathy is more commonly associated with older
T2DM patients. Proliferative retinopathy is more commonly associated with
T1DM patients29, 106, 107.
Ischemic maculopathy develops from extensive capillary occlusions within
the central retina. The macula is the centre of vision and has very high metabolic
activity. If there is inadequate perfusion due to capillary closure, atrophy sets in
and visual acuity decreases. The affected macula appears pale, has numerous
hemorrhages and microaneurysms with no exudates present. Unfortunately,
currently there is no available treatment for ischemic maculopathy.
Diabetic macular edema occurs due to the increased permeability of
retinal capillaries due to the breakdown of the BRB and micoaneurysms resulting
in extracellular fluid and thickening of the retina17. Fluid filled cystic spaces
develop within the retina and at the fovea (Figure 1.10). DME can be
characterized as either focal or diffuse vascular leakage and is also known as
exudative maculopathy due to the plasma lipoproteins which leak out, precipitate
and form hard exudates27, 29. This form of maculopathy has greater vision
threatening effects the closer it is to the macula and fovea. This hard exudate
and macular thickening disrupts the function of the central retina, causing vision
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Figure 1.10. Diabetic macular edema. (A) Fluorescein angiogram discloses
petalloid pattern of intraretinal cystoid edema in fovea. (B) Cross-sectional optical
coherence tomography showing clinically significant macular edema with cysts
and macular thickening. (C) Large cystoid spaces filled with granular
proteinaceous fluid are seen in the outer plexiform and inner nuclear layers.
Images from: Eagle RC. Eye pathology an atlas and text. Philadelphia
(Pennsylvania): Wolters Kluwer; Lippincott Williams & Wilkins; 2011.
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Figure 10 Diabetic macular
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loss. Exudative maculopathy should be treated as early as possible with laser or
anti-VEGF injections.
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1.4.4.3

Pre-proliferative Retinopathy

In pre-proliferative retinopathy, retinal capillaries continue to close
resulting in further ischemia and non-perfusion. Large, blotchy hemorrhages
begin to form within the retina. The formation of hemorrhages may be associated
with an increased number of cotton wool spots. Intraretinal microvascular
abnormality (IRMA), small vascular loops stemming from capillaries or venules,
are representative of intraretinal shunt vessels and a form of abnormal vascular
development. They may be seen particularly along the edges of regions of
capillary occlusions and non-perfusion (Figure 1.11A). The retinal vessels may
develop venous dilation, reduplication, loops and beading (Figure 1.11B and
C)27, 29. The occurrence of such changes is indicative that the patient has
transitioned into the severe stage of NPDR and is a significant predictor of future
progression towards retinal neovascularization and PDR.26, 29 Diabetic patients in
the pre-proliferative retinopathy stage do not always progress to proliferative
retinopathy but the risk is as high as 50% within the year107, 108, 109.
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Figure 1.11. Pre-proliferative retinopathy. (A) An example of intraretinal
microvascular abnormality (IRMA) in the temporal retina of the left eye (arrow).
This image was originally published in the Retina Image Bank® website. Talal
Basha. Maculopathy and IRMA Left Retina. Retina Bank. 2013;12528. © the
American Society of Retina Specialists. (B) Example of venous loops (arrows).
This image was originally published in the Retina Image Bank® website. Hamid
Ahmadieh. Venous Loop & Venous Beading. Retina Bank. 2014;18246. © the
American Society of Retina Specialists. (C) Venous beading (arrows). This image
was originally published in the Retina Image Bank® website. Henry J. Kaplan
and Niloofar Piri. Venous Beading & NVE. Retina Bank. 2013;5347. © the
American Society of Retina Specialists. (D) Fluorescein angiography displaying
severe capillary nonperfusion. This image was originally published in the Retina
Image Bank® website. Jeffrey S. Heier. Severe Capillary Nonperfusion. Retina
Bank. 2013;178. © the American Society of Retina Specialists.
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Figure 11 Pre-proliferative Retinopathy
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1.4.4.4

Proliferative Diabetic Retinopathy

With increasing retinal capillary bed closure and ischemia, retinal
neovascularization may occur. In response to ischemia, vasoproliferative growth
factors are secreted to rejuvenate the retinal perfusion, but they typically fail to do
so. The new vessels grow on the retinal surface, with the posterior surface of the
vitreous acting as a scaffold. At the edge of both perfused and non-perfused
retina, neovascularization occurs (Figure 1.12A)27. When compared to normal
vessels, the new vessels lack endothelial tight junctions, and are therefore very
permeable and fragile which may result in bleeding termed a vitreous
hemorrhage. If the bleeding is limited, a few floaters might be present which the
patient may or may not notice, however if there is extensive bleeding, there can
be an abrupt decrease in total vision. These hemorrhages typically develop when
the posterior vitreous partially detaches overlying an area of new vessel
development (Figure 1.12B). As the neovascularization continues, a fibrous
tissue web may accompany the growing new vessels and can eventually
undergo contraction over time resulting in a retinal detachment (Figure 1.12C)27.
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Figure 1.12. Proliferative diabetic retinopathy. (A) Network of blood vessels
(arrows) arising from a normal retinal vein represents neovascularization. This
image was originally published in the Retina Image Bank® website. Jason S.
Calhoun. Neovascularization. Retina Bank. 2013;7786. © the American Society
of Retina Specialists. (B) Vitreous traction on neovascular tissue in proliferative
diabetic retinopathy gives rise to vitreous hemorrhage. This image was originally
published in the Retina Image Bank® website. Carmen L Gonzalez. Proliferative
Diabetic Retinopathy. Retina Bank. 2013;9750. © the American Society of Retina
Specialists. (C) Significant fibrovascular proliferation is seen along the major
retinal vascular arcades in the left eye of this patient with proliferative diabetic
retinopathy. This image was originally published in the Retina Image Bank®
website. Daniel Rojas Abatte. Fibrovascular Proliferation. Retina Bank.
2016;26778. © the American Society of Retina Specialists.
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Figure 12 Proliferative diabetic
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1.5 Treatments
Treatments for DR follow the results of Diabetic Retinopathy Study (DRS)
and Early Treatment of Diabetic Retinopathy Study (ETDRS)27. Both were
landmark trials that set guidelines for the treatment of diabetic retinopathy. The
DRS (1972) was established to see if panretinal photocoagulation (PRP) could
prevent vision loss in patients with PDR and to assess the safety of the
procedure using different lasers104. The results of that study conclusively showed
that PRP significantly reduces serve vision loss in patients with PDR, reducing
blindness by 90%26, 110-123. For patients with PDR, DRS showed that the
treatment outweighs the risks of laser but recommended that patients with nonproliferative changes should be monitored frequently104. The ETDRS (1985) was
designed to determine the ideal stage of DR to conduct PRP, whether PRP was
effective in the treatment of macular edema, and if aspirin was effective in
altering the development of DR104. The results indicated that focal
photocoagulation reduced the risk of moderate vision loss by 50% in patients
with PDR. ETDRS showed that both early PRP before the development of highrisk PDR and the deferral of treatment until high-risk PDR develops are effective
in reducing the risk of severe vision loss. Examining this evidence, it can be
concluded that, as the eye approaches the high-risk stage of PDR, PRP should
be considered26, 124-146. ETDRS also defined the stages of DR from mild,
moderate, severe, very severe NPDR to early, high-risk PDR levels. The
classification allows physicians to correlate the level of DR with the risk of
progression and the potential outcomes of the treatments27. The definition of mild
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to moderate NPDRs is when a patient has an intraretinal hemorrhage in fewer
than the four quadrants of the retina (superior, inferior, nasal and temporal),
microanureisms, hard exudates, macular edema and abnormalities in the foveal
avascular zone. Moderate to severe NPDR is defined as having mild/moderate
intraretinal hemorrhage in four quadrants, having cotton wool spots, venous
beading and IRMAs. Severe NPDR is classified as having one of the following:
severe intraretinal hemorrhage in four quadrants, venous beading in two
quadrants, IRMA in one quadrant. Very severe NPDR is when at least two of the
three traits occur: severe intraretinal hemorrhage in four quadrants, venous
beading in two quadrants, IRMA in one quadrant. PDR has three of the following:
presence of neovessels, location and size of the neovessels, presence of preretinal hemorrhage or vitreous hemorrhage103. The two treatments used clinically
for DR are PRP for PDR and the use of anti-VEGFs for DME.
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1.5.1 Panretinal Photocoagulation
PRP is a laser technique employing a visible laser treatment used to
destroy select portions of the peripheral retina to reduce oxygen consumption
and to restore the balance between oxygen supply and demand95. A patient is
administered pain numbing medication in the form of proparacaine drops to the
eye, the pupil is dilated and a contact lens is placed on the cornea17. Mild to
moderate laser burns that produce a light grey spot on the retina are delivered in
a grid-like pattern, sparing the macula and optic nerve, for a total of 1800-2400
burns of 500 µm in diameter delivered over 1-4 treatment sessions (Figure
1.13A)17, 95. The laser ray is absorbed by the melanin in the retinal pigment
epithelium and causes thermal coagulation of RPE cells and the adjacent
photoreceptors (Figure 1.13B). Photoreceptors use more oxygen than most cells
in the body, and in this oxygen deprived environment, eliminating them is an
effective method to reestablish the balance and reduce the oxygen consumption
of the retina95. The photoreceptors, over time, are replaced by glial cells and
oxygen from the vascular choroid can diffuse through the scars in the outer retina
to reach the hypoxic inner retina (Figure 1.14A). The whole process increases
the oxygen tension and improves hypoxia95, 147-152. Since hypoxia is the stimulant
for VEGF and neovascularization, the increased oxygen supply results in a
stabilization of VEGF production back to normal levels, decreasing endothelial
cell proliferation, decreasing permeability and decreasing neovascularization
(Figure 1.14B). Overall, the treatment reduces the oxygen consumption and the
number of photoreceptors in the outer retina by approximately 20%95.
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Figure 1.13. Panretinal photocoagulation. (A) Ultra-wide field OPTOS
photograph taken after panretinal photocoagulation in a patient with proliferative
diabetic retinopathy. (B) The outer retina and retinal pigment epithelium are
photocoagulated and the photoreceptors are absent, whereas the inner retina is
relatively intact. Image from: Stefánsson E. The Mechanism of Retinal
Photocoagulation – How Does the Laser Work? European Ophthalmic Review
2009;02(01):76-79.
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Figure 13 Pan
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Figure 1.14. Effect of panretinal photocoagulation treatment. (A) The oxygen
flux is represented by a black arrow, coming from the choroid and passing
through a laser scar into the inner retina. In the laser scar, photoreceptors are
replaced by glia and the oxygen consumption is decreased. The oxygen flux from
the choroid would normally be consumed by the photoreceptors, indicated by the
green arrow. As the oxygen consumption of the glia is less than that of
photoreceptors, the oxygen flux reaches the inner retina. (B) The schematic flow
diagram explains the mechanism by which retinal photocoagulation affects retinal
neovascularization and macular edema in diabetic retinopathy and other
ischemic retinopathies. RPE = retinal pigment epithelial. Adapted from:
Stefánsson E. The Mechanism of Retinal Photocoagulation – How Does the
Laser Work? European Ophthalmic Review 2009;02(01):76-79.
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Figure 14 Effect of
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Laser can also be administered as a focal treatment for macular edema to
ablate leaky microaneurysms around the macula and reduce swelling. This
decreases the hydrostatic pressure of capillaries and venules, decreasing water
flux from the vasculature to the tissue according to Starling’s law and reducing
edema formation95. Focal laser is administered at a diameter of 100-200 µm to
seal the small leaky microaneurysms around the macula17.
Based on the ETDRS, the current guidelines for diabetic retinopathy
from the Royal College of Ophthalmologists state that patients with mild or
moderate NPDR do not require treatment but require annual monitoring and are
advised to maintain good glycemic control153. Patients with severe NPDR require
closer monitoring with an assessment every 6 months to detect progression of
the disease to PDR. In T2DM patients with very severe NPDR, PRP can be
considered if the patient is an older T2DM, monitoring of DR is difficult due to
compliance or obscured view of retina, prior cataract surgery and if vision has
been lost in one eye. Patients with PDR urgently require PRP to prevent vision
loss104. Since the primary goal of focal laser treatment is to reduce the risk of
further vision loss and not to improve vision, treatment with focal laser for
patients with macular edema should be considered when the macula is under the
risk of being damaged even when vision is 20/2026, 27.
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1.5.2 Anti-VEGF Therapy
VEGF is involved in neovascularization, increased vascular permeability
and the development of diabetic macular edema. Anti-VEGF treatment has
become the gold standard for treating centre-involved diabetic macular edema
(edema within the macula)5. In humans, VEGF family consists of VEGF-A, -B, -C,
-D and placental growth factor (PlGF)154-156. VEGF-A is the key target in
antiangiogenic therapy since it is the major driver of pathological angiogenesis
and is involved in increased permeability in DME154. As a result of alternative
splicing and cleavage, VEGF-A is subdivided into several different isoforms154,
155

. The VEGF-A isoforms differ in their size and their ability to bind heparin or

neuropilins, but are all active as dimers154.
Over time, new forms of anti-VEGFs have been developed that have
increased affinity for VEGF-A as well as an ability to inhibit a broad range of
isoforms and other family members of VEGF, thus increasing the anti-angiogenic
activity154. The three VEGF inhibitors used clinically are bevacizumab (Avastin),
ranibizumab (Lucentis) and aflibercept (Eylea) (Figure 1.15)5. Anti-VEGF
treatment is administered through a transcleral intravitreal injection in the office
setting. The therapy aims to decrease macular swelling through inhibiting the
actions of VEGF by preventing the binding of VEGF to its receptor. As the result
of inhibition, vascular permeability, endothelial cell proliferation and endothelial
cell migration are significantly reduced154, 155.
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Figure 1.15. Anti-VEGF agents clinically used for DME treatment. Molecular
differences between VEGF inhibitors. Aflibercept is a fusion protein consisting of
the key VEGF-binding domains of human VEGF receptors 1 and 2. Bevacizumab
is a recombinant, full-length humanized monoclonal antibody and ranibizumab is
an affinity-matured antigen-binding fragment (Fab) of the antibody derived from
bevacizumab.
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Figure 15ant
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Bevacizumab (Avastin) is a recombinant, full-length humanized
monoclonal antibody that binds all known isoforms of VEGF-A154. The drug is
approved for the treatment of colorectal cancer but does not have Health Canada
approval for intraocular use and is thus used off-label154, 157, 158.
Ranibizumab (Lucentis) was developed for intravitreal administration to
treat wet age-related macular degeneration and has subsequently been
approved by Health Canada for DME. Ranibizumab (Lucentis) is an affinitymatured antigen-binding fragment (Fab) of the antibody derived from
bevacizumab (Avastin)5, 154. Ranibizumab (Lucentis) has approximately 2.5 times
greater affinity for VEGF, has been shown to be more effective than
Bevacizumab (Avastin) and inhibits all known VEGF-A isoforms159, 160.
Aflibercept (Eylea), also known as VEGF trap, is a human recombinant
fusion protein consisting of the key VEGF-binding domains of human VEGF
receptors 1 and 2160. Overall, VEGF trap is the second Ig domain of human
VEGFR1 and the third Ig domain of human VEGFR2 expressed as an inline
fusion with the constant region (Fc) of human IgG1154, 161. Similar to bevacizumab
and ranibizumab, aflibercept (Eylea) binds multiple isoforms of VEGF-A but is
also capable of binding to VEGF-B and PlGF which are involved in vascular
remodelling154, 162. Aflibercept (Eylea) is a potent drug, binding to VEGF-A with
much greater affinity and a faster association rate than ranibizumab (Lucentis) or
bevacizumab (Avastin). In 2014, Aflibercept was approved by Health Canada for
the use in wet age-related macular degeneration and DME163.
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In two masked phase 3 clinical trials named RISE and RIDE, monthly
injections of ranibizumab with and without laser were compared to the gold
standard at the time, focal laser, with findings that visual acuity improved
compared to a sham injection over a two year time period163. In the RISE study,
44% of patients treated with ranibizumab had an improvement in central vision by
15 letters or more compared to 18% in the control arm. In the RIDE study, 33%
of patients intravitreally injected with ranibizumab at a dose of 0.3 mg and 45% of
patients at a dose of 0.5 mg gained 15 letters or more, indicating that 0.5 mg
should be the clinical dose administered to patients163, 164. Another study,
RESTORE, found that a dose of 0.5 mg of ranibizumab administered once a
month for 3 months followed by an as-needed treatment thereafter significantly
improved visual acuity and reduced macular thickness in patients163, 165. The
study helped establish the gold standard for treatment of DME patients in clinic.
However, the effects of ranibizumab injections do not last in all patients and
many patients require repeated injections to sustain the beneficial effects5.
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1.6 Risks
1.6.1 Panretinal Photocoagulation
Although laser surgery is often considered painless, when the peripheral
retina is being treated, it is common for the patients to experience some
discomfort or pain26, 166. To minimize the pain associated with the procedure,
patients are given topical anesthetic and Tylenol post-treatment. To further
reduce the stress, PRP is often administered in multiple sessions to minimize
pain and improve patient experience.
A potential complication of PRP may be the development or digression of
edema post-PRP. If the laser is too powerful, the ray may disrupt BRB and fluid
can leak from the choroid into the retina. However, BRB is usually restored after
7-10 days167. To reduce edema, physicians break up PRP treatment into multiple
sessions to reduce the number of burns and thus the overall risk166.
As a result of the treatment, PRP destroys the peripheral photoreceptors
of the retina to reduce oxygen consumption, leading to a slight visual field loss.
The negative impact is well established and has been documented by numerous
studies showing that in the short-term, visual field depression is stable166.
Some patient’s post-PRP may have diminished colour vision. The finding
has been reported in ETDRS and it is proposed that it may potentially lead to
direct cone destruction167. In order to reduce the risk of the side effect, laser
treatments should be administered in multiple sessions and at minimal duration
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and intensity166, 167. Several patients have reported decreased night vision and
transient contrast sensitivity post-PRP, although, the degree to which PRP
affects either is not fully understood166, 168. Studies have noted that diminished
night vision and contrast sensitivity are potential side effects of severe
retinopathy. As such, it is difficult of establish whether the effects experienced by
the patients are due to the laser treatment or the progression of the disease168.
Post-laser, choroidal effusions or retinal detachments may occur which
may lead to narrowing of the anterior angle, increased IOP or angle-closer
glaucoma. This risk is further minimized when treatment is administered in
multiple sessions166.
Post-laser, posterior segment complications, such as a vitreous
detachment, may occur. The detachment may be partial or complete and may
cause a retinal tear or elevate new vessels causing retinal hemorrhage to
develop167. The application of burns with the laser may cause a formation of
epiretinal membrane. An epiretinal membrane is a thin sheet of fibrous tissue that
forms over the surface of the macular area of the retina. Surgical procedure is
required to treat the complication.
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1.6.2 Anti-VEGF Therapy
Since anti-VEGF therapy is administered through an intravitreal injection,
the main risk is the development of endophthalmitis, an intraocular infection
involving the aqueous and vitreous33, 169. The incidence of developing
endophthalmitis is 0.019-1.6%, with the reported rate in recent studies skewing
towards the lower incidence rate169. The most important factor in reducing the risk
of endophthalmitis is maintaining sterility through the use of topical antiseptic
such as 5% povidone-iodine solution169. During the injection, it is very important
to avoid any contact of the sterile needle with the lashes and eyelids of the
patient.
Intraocular inflammation occurs in approximately 1.4-2.9% of patients
undergoing intravitreal injections of anti-VEGFs169, 170. As opposed to the
infectious endophthalmitis which develops over 2.55 days, acute intraocular
inflammation occurs less than 1 day post-injection. Physicians recommend that
patients who arrive to the clinic with the symptoms of intraocular inflammation
should be treated as potentially being affected with endophthalmitis and
administer intravitreal antibiotics169, 170.
There is a 0-0.67% chance of developing a rhegmatogenous retinal
detachment after intravitreal injection likely due to the creation of a posterior
vitreous detachment or improper needle placement169, 171, 172. Monitoring the
technique and using smaller gauge needles is recommended to avoid the retinal
detachment.
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Intravitreal injections have been documented to cause acute IOP
elevation that last several hours169, 173, 174. Numerous theories have been
proposed to address the cause of the issue. More prominent theories suggest
that IOP elevation may be due to pharmacologic effects of blocking VEGF, an
inflammatory mechanism, or impaired/damaged outflow due to repeated
injections175. Topical glaucoma eye drops may be prescribed to lower the acute
IOP. Patients with sustained increases in IOP require routine monitoring.
Hemorrhages have been reported in patients post-injection.
Subconjunctival hemorrhage or bleeding underneath the conjunctiva of the eye
has been reported in roughly 10% of treatments, with patients receiving aspirin
having a much higher frequency. In fewer cases, subretinal hemorrhages have
also been reported although discontinuing anticoagulants is not advised for the
patients due to risk of thromboembolic events169, 176-182.

69

1.7 Rationale
Over the past decade, there have been increased clinical reports of
diabetic patients either post-PRP or treated with anti-VEGFs developing signs of
glaucoma and optic neuropathy. The issue has been publicly discussed by Dr.
Marianne Edwards in her presentation, “Post-Anti-VEGF injection related
glaucoma,” at the 2014 Canadian Ophthalmological Society Annual Meeting.
With the continued and increased use of intraocular anti-VEGF treatments and
PRP being the gold standard treatment used to stabilize and control proliferative
disease, numerous questions have been raised. Do these treatments increase
the risk of developing glaucoma? What are the long-term effects of these
treatments on the optic nerve? None of these questions have been examined in
patients with DR nor have the effects of these treatments on retinal perfusion
have been assessed. Controlled trials that not only look at visual acuity and
central thickness but also retinal and optic structures are greatly needed to
substantiate the safety and efficacy of PRP therapy and anti-VEGF drugs.
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1.8 Hypothesis
The current study is based on the hypothesis that:
A)

In respect to PRP treatments, PASCAL photocoagulation is a safe and

effective panretinal laser treatment that will not cause structural and functional
changes in the retina and optic nerve, specifically changes to total retinal
thickness, thickness of the nerve fiber layer and optic nerve cupping.
B)

Regarding anti-VEGF treatment, increased exposure to anti-VEGF will

result in increased retinal cell death and morphological changes to the optic
nerve.
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1.9 Specific Aims
PRP Treatment
1. To use structural (OCT, HRT) and functional (visual field, visual acuity)
diagnostic systems to monitor the total retinal thickness, nerve fiber layer
of the macula, optic nerve and visual field to see if there are any
progressive long term changes following the PASCAL laser system.
2. To quantify the amount of ischemia to PRP performed.

Anti-VEGF Treatment
3. To describe the effects of anti-VEGF injections and the frequency of
injections on the structural and functional changes to the retina and optic
nerve of DR patients with underlying DME using in vivo clinical
pathological analysis.
4. To evaluate the effect of VEGF inhibition on neuronal cells in a STZinduced diabetic rat retina by performing intravitreal anti-VEGF injections
with different doses.
5. To determine if exposure to different doses of anti-VEGF alter retinal
cells metabolic activity and function or induce toxicity by various
colorimetric assays.
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Chapter 2

2

The structural and functional changes to the retina and
optic nerve following panretinal photocoagulation over a
2-year time period1

The chapter addresses specific objectives outlined in aims 1 and 2:
1. To use structural (OCT, HRT) and functional (visual field, visual acuity)
diagnostic systems to monitor the total retinal thickness, nerve fiber layer
of the macula, optic nerve and visual field to see if there are any
progressive long term changes following the PASCAL laser system.
2. To quantify the amount of ischemia to PRP performed.

1

Parts of this work have been published in the following manuscript:
•

Filek R, Hooper P, Sheidow T, Gonder J, Varma D, Heckler L, Hodge W,
Chakrabarti S, Hutnik CML. Structural and functional changes to the retina
and optic nerve following panretinal photocoagulation over a 2-year time
period. Eye (Lond). 2017 Apr 28. doi: 10.1038/eye.2017.66. [Epub ahead
of print]. Eye applies the License to Publish to works. Under section 2 of
this license, authors retain ownership of the copyright for their content. No
permission is required from the publishers.
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2.1 Introduction
Diabetic retinopathy (DR) is the leading cause of blindness among
working-aged adults that affects more than 141 million adults worldwide1, 2. Over
the past 40 years, epidemiological studies and clinical trials have demonstrated
that timely laser photocoagulation treatment can prevent vision loss in DR
patients. Panretinal photocoagulation (PRP) has been shown to stabilize and
control the proliferative disease and, since the Diabetic Retinopathy Study, has
become the gold standard treatment3, 4. Whereas there are reports of PRP
resulting in visual field changes, few studies have looked at the impact the
procedure has on the optic nerve, especially the long-term effects5. The risk of a
concurrent diagnosis of treated DR and normal tension glaucoma exists without
adequate awareness of the potential impact of PRP on the appearance of the
optic nerve head. While PRP has revolutionized how DR patients are managed,
the long-term structural and functional effects of PRP on the retina and optic
nerve remain to be determined.
Several studies have looked at the short-term effects of PRP on the retina.
The Manchester Pascal Study Report 3 expanded on these projects by looking at
the short-term effects of Pascal laser on the retinal nerve fiber layer over the
course of 12 weeks6, 7. A major limitation of the previous studies has been the
relatively short-term evaluation of the effects. Furthermore, despite the evident
need, no study has looked at the long-term consequences of the laser treatment

101

on the retina or established whether the observed changes were due to the laser
or progression of diabetes.
The purpose of the following study is to evaluate retinal and optic nerve
changes using structural and functional diagnostic tests at 6, 12, and 24 months
in DR patients post laser treatment. This is the first comprehensive study to
investigate the long-term structural and functional effects of PRP on the retina
and optic nerve that involves analysis of macular thickness, the RNFL, mean
perfusion, vertical C/D ratio, cup volume, stereo photos, IOP, visual acuity and
visual fields.
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2.2 Methods
The following was a prospective study conducted at the Ivey Eye Institute,
a tertiary care academic center in London, Ontario, Canada. The study complies
with Declaration of Helsinki and was approved by Health Sciences Research
Ethics Board of Western University. Prospective, treatment- naïve patients over
the age of 18 years who had severe non-proliferative and proliferative DR,
according to the ETDRS guidelines, and required PRP were recruited into the
study. Participants were excluded from the study if they had advanced lens
opacity or cataract that could affect diagnostic testing, history of glaucoma or any
other disorder of the optic nerve (optic neuropathy, neuritis, uveitis or retinal
degeneration), presence of macular edema (central macular thickness >300 μm)
and prior retinal treatment (PRP, focal laser or surgery within 6 months of
participation). All participants provided informed consent. From this group, eight
patients who did not receive laser treatment, as the diabetic retinopathy was at
the severe non-proliferative state, were chosen as the control. Participants were
evaluated at baseline (pre-laser), 6, 12, and 24 months post-laser. During each
study visit, participants underwent optical coherence tomography (OCT),
Heidelberg Retinal Tomography (HRT), visual field (VF) and intravenous
fluorescein angiography (IVFA) testing as well as a standard ophthalmic exam
which included best-corrected Snellen visual acuity (BCVA), intraocular
measurement using Goldmann applanation tonometry, and slip lamp
examination. Humphrey 24-2 SITA visual field testing was performed with
undilated eyes.
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2.2.1

Optical Coherence Tomography
Macular thickness, optic disc cube and HD 5 line raster images were

obtained using OCT (Cirrus HD-OCT 4000, Carl Zeiss Meditech, Dublin,
California). The principles and the protocol have been previously described in
detail7, 8, 9, 10. OCT tests were taken at baseline, 6, 12, and 24 months post-laser.
Each scan was repeated 3 times to ensure collection of the highest signal
strength.
Analysis of the macula were performed using 6 x 6 mm scans with 512 x
128 resolution (128 horizontal scan lines consisting of 512 A-scans). The
macular thickness was displayed as 3 concentric circles, with a 1 mm diameter
central circular subfield, a 3 mm diameter inner ring, and a 6 mm diameter outer
ring. Each ring was divided into superior, inferior, nasal, and temporal
quadrants7. When performing a scan of the optic nerve, a 3.4 mm ring was
centered on the optic nerve and 768 A-scans were performed11, 12. The average
RNFL thickness and vertical C/D ratio were measured. To analyze images of the
retinal structure, HD 5 line raster was performed. This high-density scan
performs 4,096 A-scans in five planes to provide a highly detailed image12.

2.2.2

Heidelberg Retinal Tomography
Imaging of the optic nerve was performed by Heidelberg Retina

Tomograph II. The scanning protocol has been previously described in detail13, 14.
Each scan was repeated 3 times to allow for selection of a scan with low
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standard deviation. In brief, the optic disc margin contour line was marked at the
inner border of the scleral ring by observing disk images. Once the contour line
was marked, a standard reference plane was placed 50 μm posterior to the mean
retinal height between 350° and 356° along the contour line15. The area
superficial to the reference plane is considered to be the neuroretinal rim while
the area deep to the plane is considered to be the cup. HRT software analyzes
the shape of the optic nerve and determines, based on the set of stereometric
parameters, whether it is within or outside of the normal limits. These parameters
were also used to calculate the glaucomatous progression16.

2.2.3

Humphrey Visual Field Analyzer
Standard Humphrey 24-2 SITA testing algorithm was performed on

Humphrey Field Analyzer, model 750i (Zeiss Humphrey Systems, Dublin, CA,
USA). In 24-2 SITA testing algorithm, 54 individual points were tested. The
threshold values calculated from the individual points were then compared to a
normative database for similar aged normal-sighted individuals17. Data with
fixation losses and false negative responses greater than 20% and false positive
responses greater than 15% were excluded from the study16.

2.2.4

Wide-Field Fluorescein Angiogram and Quantification of
Ischemia
Angiography was performed on Optos 200 Tx with an intravenous

injection of 5 ml of 10% sodium fluorescein18. Digital stereoscopic photographs
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and IVFA images were taken. The best IVFA image, obtained during the
arteriovenous phase of each patient, was used to quantify the amount of
ischemia. The uncompressed tiff images were transferred from the Optos V2
Vantage Review Software to Adobe software (Adobe Systems, Inc, San Jose,
CA) for analysis.
Two graders quantified the amount of ischemia in each patient using the
concentric rings method which has been previously described in detail19. In the
method, the innermost circle is first centered on the optic nerve to be sized
proportionately and then repositioned to be fovea-centered. The 12 segments in
each of the rings were graded as, “perfused,” or “non-perfused,” based upon
whether more than 50% of the segment showed either a perfused or nonperfused morphology. The classification of “non-perfused” and “perfused”
morphology was taken from the SCORE study. In the control and PRP laser
eyes, “non-perfused” was characterized by a darker appearance of the retina and
pruned tree appearance (narrowed and difficult to see) of surrounding arterioles.
“Perfused” morphology was characterized by its clear ground-glass opacity20.
Calculations of the mean perfused ratio were performed using the mean
perfusion ratio = area perfused/ (area perfused + non-perfused). Each segment
in each of the rings was given a value of either 0 indicating non-perfused or 1
indicating perfused retina.
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2.2.5

Optic Nerve Grading
Stereoscopic photographs were taken with Optos 200 Tx at baseline, 6,

12, and 24 months post-laser. Optic nerve photographs were cropped to a size of
4 x 4 mm for grading. Two glaucoma specialists independently graded the C/D
ratio of the laser treated eyes and control eyes of diabetic patients not requiring
laser. The graders were masked to the type of patients and purpose of the study.

2.2.6

Pattern Scan Laser Photocoagulator (Pascal)
Pascal laser is a semi-automated 532 nm frequency-doubled neodymium-

doped yttrium aluminum garnet (Nd:YAG) solid-state laser21. The laser was
applied in a pattern array using very short pulse durations of 10-20 ms for each
burn with typically a higher power compared to conventional photocoagulation
(100 mW and 100 ms pulse duration). All patients received PRP with a pulse
duration of 20 ms and a spot size of 200 mm. Power of the laser beam varied
between 430 and 600 mW to achieve a mild gray-white burn intensity, which
according to the ETDRS guidelines, is a grade 2+ and 3+ burn. Patients
received a mean ± standard deviation of 1720.8± 392.3 laser spots ranging from
1125 to 2125 spots. Between sessions, there was an interval of two to three
weeks.

2.2.7

Statistical Analysis
Statistical analysis was performed using GraphPad Prism 5 (GraphPad

Software, La Jolla, CA). For statistical analysis, Snellen BCVA measurements
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were converted to logarithm of the minimum angle of resolution (logMAR) scores.
Unpaired t-test was used to compare the average age and Fisher’s exact test
was used to compare the percentage of female participants between control and
PRP laser groups. Paired t-test was used to compare differences at specified
points over time in PRP treated and control groups. Repeated measures ANOVA
with Bonferroni's multiple comparison test was used to statistically analyze the
interval changes of measurements in PRP laser and control groups at baseline,
6, 12, and 24 months, respectively. ANOVA with Bonferroni method was
performed as outlined in J Neter, W Wasserman, and MH Kutner, Applied Linear
Statistical Models, 3rd edition, Irwin, 1990. All data was expressed as mean ± SD
and accepted as statistically significant if p<0.05. A correction of p<0.017 was
applied for the Bonferroni's multiple comparison test.
To calculate sample size with an overall power of 80%, p<0.05 was used
as an acceptable significance level. Using a two-tailed test for a control with an
optic nerve of size 0.3 and an atrophy group of size 0.6, both derived from
cup/disk ratio, the effect size would be 0.3. Adding the values to the sample size
calculation, 16 patients would be needed for an 80% power number. Twenty
diabetic patients requiring PRP were recruited into the study but four were
removed due to patient compliance. Eight patients were used as diabetic controls
not requiring laser. The diabetic control group did not have proliferative disease
that developed during the two year study period. They were included to ensure
that the observed changes could be correlated with the laser treatments and not
due to diabetic disease progression itself.
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2.3 Results
A single eye from each of the 16 patients requiring PRP and 8 control
patients not requiring PRP, who were recruited between December 20, 2013, to
December 27, 2015, were analyzed. The average age of patients was 70.6 ± 8.4
years for the control group and 65.7 ± 12.5 years for the PRP laser group. The
control group had 37.5% female participants while the PRP laser group had 25%
female participants. The control and PRP laser groups did not significantly differ
(p>0.05) in any of these categories (Table 2.1). None of the patients developed
diabetic macular edema during the study.
Following laser treatment, the macular thickness (Figure 2.1A) increased
by 3.9 µM at 6 months (298.10 ± 29.02 µM, p=0.44) relative to baseline (294.20 ±
24.20 µM). The macular thickness recovered to 293.30 ± 20.99 µM at 12 months
(p=0.82) and 291.90 ± 25.41µM at 24 months (p=0.74). Compared to baseline
(276.60 ± 35.36 µM), the control group showed no significant change in macular
thickness at 6 months (273.40 ± 29.22 µM, p=0.27), 12 months (274.90 ± 33.48
µM, p=0.72), and 24 months (272.80 ± 36.51 µM, p=0.31).
RNFL thickness (Figure 2.1B) increased at 6 months (86.25 ± 12.07 µM,
p=0.14), 12 months (85.50 ± 9.70 µM, p=0.29) and 24 months (84.38 ± 13.09
µM, p=0.56) compared to baseline (82.75 ± 11.38 µM). The control group had no
significant change in RNFL thickness at 6 months (74.88 ± 9.96 µM, p=0.51), 12
months (74.38 ± 8.78 µM, p=0.93), and 24 months (72.75 ± 9.15 µM, p=0.40)
compared to baseline (74.25 ± 10.39µM). Analyzing each region, there was no
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Table 2.1. Patient demographics
Control

PRP Laser

P-Value

Number of eyes

8

16

-

Average age
(years± SD)

70.6±8.4

65.7±12.5

0.33*

Female
Participants (%)

37.5%

25%

0.65†

Mean laser spots
± standard
deviation

-

1720.8± 392.3

-

*Unpaired t test
†Fisher’s exact test
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Figure 2.1. Interval changes in (A) macular thickness, (B) RNFL thickness and
(C) mean perfused ratio at baseline, 6, 12, and 24 months later in the control and
PRP laser groups. p-value: control group differences between baseline and postfollow-up measurements, paired t-test. p'-value: PRP laser group differences
between baseline and post-laser measurements, paired t-test.
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Figure 16 chapter 2 figure 1 Interval changes in (A) macular thickness, (B) RNFL
thickness and (C) mean perfused ratio at baseline, 6, 12, and 24 months later in the
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significant difference in thickness in the superior, inferior, temporal and nasal
regions of the RNFL for both the control and PRP laser groups (P ≥ 0.18) (Table
2.2).
The mean perfused ratio showed no significant difference at 6 months
(0.45 ± 0.15, p=0.16) but a significant improvement at 12 months (0.47 ± 0.14,
p=0.02) and 24 months (0.49 ± 0.15, p=0.02) compared to baseline (0.44 ± 0.15)
(Figure 2.1C). There was no significant difference in the control group at 6
months (0.61 ± 0.21, p=1.00), 12 months (0.61 ± 0.22, p=0.68) and 24 months
(0.61 ± 0.22, p=0.80) compared to baseline (0.61 ± 0.21).
Analysis of the optic nerve and the associated vertical C/D ratio by OCT
(Figure 2.2A) showed a slight increase at 6 months (0.48 ± 0.19, p=0.43), 12
months (0.47 ± 0.20, p=0.61) and 24 months (0.47 ± 0.19, p=0.0.62) compared
to baseline (0.46 ± 0.19). Vertical C/D ratio remained consistent in the control
group, being 0.52 ± 0.29 at baseline, 0.54 ± 0.23 at 6 months (p=0.57), 0.54 ±
0.24 at 12 months (p=0.64) and 0.54 ± 0.27at 24 months (p=0.37).
Analysis of the optic nerve and the corresponding vertical C/D ratio using
the HRT (Figure 2.2B) showed an increase at 6 months (0.33 ± 0.30, p=0.24)
compared to baseline (0.27 ± 0.26) in the PRP laser group. The ratio remained
elevated at 12 months (0.32 ± 0.28, p=0.34) and 24 months (0.31 ± 0.28, p=0.44)
post-laser. Vertical C/D ratio showed no significant difference in the control group
at 6 months (0.34 ± 0.31, p=0.61), 12 months (0.32 ± 0.30, p=0.44) and 24
months (0.33 ± 0.29, p=0.51) compared to baseline (0.35 ± 0.28).
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Table 2.2. Changes in RNFL thickness (µm) over the course of 24 months in the
control and PRP laser groups.
Baseline

6 months

12 months

24 months

PValue*

Average
Control
PRP Laser

74.25 ± 10.39
82.75 ± 11.38

74.88 ± 9.96
86.25 ± 12.07

74.38 ± 8.78
85.50 ± 9.70

72.75 ± 9.15
84.38 ± 13.09

0.41
0.42

Superior
Control
PRP Laser

83.25 ± 18.38
100.00 ± 18.35

82.75 ± 14.96
103.38 ± 17.04

81.13 ± 14.93
101.75 ± 17.30

79.75 ± 12.83
103.25 ± 23.13

0.30
0.78

Inferior
Control
PRP Laser

85.25 ± 12.52
97.19 ± 19.90

86.38 ± 14.14
102.38 ± 18.79

84.88 ± 17.63
101.56 ± 15.74

85.75 ± 17.65
99.13 ± 21.87

0.95
0.48

Temporal
Control
PRP Laser

62.75 ± 15.15
66.38 ± 12.84

64.00 ± 14.31
68.56 ± 11.87

62.25 ± 10.73
69.13 ± 10.21

58.75 ± 16.42
65.19 ± 11.02

0.18
0.21

Nasal
Control
PRP Laser

66.00 ± 11.41
67.44 ± 8.22

66.5 ± 8.65
70.56 ± 9.13

68.88 ± 8.11
69.44 ± 10.94

66.5 ± 7.05
69.75 ± 14.57

0.62
0.66

Table 3RNFL = retinal nerve fiber layer
*Repeated Measures ANOVA
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Figure 2.2. Interval changes in vertical cup/disk ratio measured on the (A) OCT
and (B) HRT at baseline, 6, 12, and 24 months later in the control and PRP laser
groups. p-value: control group differences between baseline and post-follow-up
measurements, paired t-test. p'-value: PRP laser group differences between
baseline and post-laser measurements, paired t-test.
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Figure 17 Interval changes in vertical cup/disk ratio measured on the (A) OCT and
(B) HRT at baseline, 6, 12, and 24 months later in the control and PRP laser groups.
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Two glaucoma specialists were assigned to independently grade the
vertical C/D ratio in the same eyes following PRP laser using stereo photographs
(Figure 2.3A). Grader 1 indicated at baseline, the mean vertical C/D was 0.44 ±
0.17 and noted an increase at 6 months (0.46 ± 0.17, p=0.08), 12 months (0.46 ±
0.16, p=0.15) and 24 months (0.47 ± 0.16, p=0.13) post-laser. Grader 2 indicated
baseline mean vertical C/D ratio of 0.35 ± 0.17 and noted a significant increase
at 6 months (0.37 ± 0.18, p=0.04), and 12 months (0.38 ± 0.18, p=0.02) with a
further increase at 24 months (0.40 ± 0.19, p=0.005) post-laser. The graders also
graded control eyes of diabetic patients not requiring laser treatment. Both grader
1 and 2 found that over 24 months there was no significant difference (p ≥ 0.10)
(Figure 2.3B).
After the laser treatment, visual field tests had an average baseline mean
deviation (MD) (Figure 2.4A) in the PRP laser group of -4.39 ± 3.10 dB. Mean
MD digressed at 6 months by 1.30 dB (-5.68 ± 5.03 dB, p=0.24) and further
significantly decreased at 12 months (-5.73 ± 4.07 dB, p=0.02) and 24 months
(-6.36 ± 3.74, p=0.01) post-laser. Control group showed no significant differences
in visual field mean MD at baseline (-8.46 ± 8.83 dB), 6 months (-8.43 ± 6.29 dB,
p=0.98), 12 months (-7.41 ± 4.78 dB, p=0.53) and 24 months (-9.19 ± 6.35 dB,
p=0.64).
Baseline mean best-corrected visual acuities (Figure 2.4B) were 0.32 ±
0.24 logMAR in the control group and 0.34 ± 0.31 logMAR in the PRP laser
group. Visual acuity slightly increased to 0.3 ± 0.29 logMAR at 6 months (p=0.32)
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Figure 2.3. Interval changes in vertical cup/disk ratio as measured by two
masked glaucoma specialists using stereo photographs at baseline, 6, 12, and
24 months later in the (A) PRP laser group and the (B) control group. p-value:
grader 1 differences between baseline and post-laser measurements, paired ttest. p'-value: grader 2 differences between baseline and post-laser
measurements, paired t-test.
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Figure 18 Interval changes in vertical cup/disk ratio as measured by two masked
glaucoma specialists using stereo photographs at baseline
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Figure 2.4. Interval changes in mean deviation measured on the (A) Humphrey
Visual Field Analyzer and (B) visual acuity at baseline, 6, 12, and 24 months later
in the control and PRP laser groups. p-value: control group differences between
baseline and post-follow-up measurements, paired t-test. p'-value: PRP laser
group differences between baseline and post-laser measurements, paired t-test.
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Figure 19 Interval changes in mean deviation measured on the (A) Humphrey
Visual Field Analyzer and (B) visual acuity
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but gradually decreased to 0.36 ± 0.33 logMAR at 12 months (p=0.58) and 0.38 ±
0.30 logMAR at 24 months (p=0.37) post-laser. Visual acuity remained consistent
in the control group, being 0.32 ± 0.24 logMAR at baseline, 0.29 ± 0.23 logMAR
at 6 months (p=0.59), 0.31 ± 0.21 logMAR at 12 months (p=0.90) and 0.33 ± 0.20
logMAR at 24 months (p=0.85). The changes were not statistically significant.
After Pascal photocoagulation, intraocular pressure (IOP) (Figure 2.5)
significantly decreased (p=0.04) by 1.5 mmHg at 6 months (17.31 ± 3.26 mmHg)
compared to baseline (18.81 ± 4.04 mmHg). The pressure remained at 17.31 ±
3.05 mm Hg at 12 months (p=0.12) but then increased close to control values
(18.25 ± 3.98 mmHg) at 24 months (p=0.68). In the control group, IOP remained
constant, being 17.38 ± 2.00 mmHg at baseline, 17.13 ± 2.59 mmHg at 6 months
(p=0.81), 17.00 ± 1.69 mmHg at 12 months (p=0.70) and 17.50 ± 3.30 mmHg at
24 months (p=0.93). The changes were not statistically significant.
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Figure 2.5. Interval changes in intraocular pressure at baseline, 6, 12, and 24
months later in the control and PRP laser groups. mm Hg= millimeter of mercury.
p-value: control group differences between baseline and post-follow-up
measurements, paired t-test. p'-value: PRP laser group differences between
baseline and post-laser measurements, paired t-test.
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Figure 20 Interval changes in intraocular pressure at baseline, 6, 12, and 24 months
later in the control and PRP laser
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2.4 Discussion
PRP laser used in this study was Pascal Pattern Scan Laser (OptiMedica,
Santa Clara, CA, USA). Compared to conventional photocoagulation lasers
which use lower power (100 mW) and longer pulse duration (100 ms), Pascal
laser is applied in a pattern array, using very short pulse durations of 10-20 ms
for each burn, and typically outputs a higher power. As a result, researchers have
suggested that Pascal laser may promote healing while causing less collateral
damage compared to conventional photocoagulation lasers22. Despite
differences between Pascal laser and conventional argon laser for PRP, past
studies have shown that there are no significant differences in the outcomes for
patients between the two lasers, showing similar effects on the regression of
DR22-25.
The macular and RNFL thickness (Figures 2.1A and B) showed an
increase at 6 months and a decrease by 24 months post-laser indicating
recovery. Past studies have described similar increases in thickness pre-6
months, likely due to post-laser intraretinal inflammation7, 26, 27. Photocoagulation
creates thermal and photochemical damage, resulting in the production of
reactive oxygen species (ROS).27 ROS generate an immune response in the
retinal tissue by increasing the intraretinal junctional permeability and recruitment
of leukocytes7, 27-31. The decrease of the thickness post-6 months suggests that
the effects of an inflammatory response persist up to 6 months in the retinal
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tissue following laser treatment. Overall, by 24 months, there was no significant
change in the macular or RNFL thickness compared to pre-treatment state.
To determine whether the observed changes were due to the laser
treatment or diabetes itself, the amount of ischemia was quantified using the
mean perfused ratio. The mean perfused ratio was calculated by the concentric
rings method utilized by Nicholson et al19. Compared to the standard ischemic
index method wherein the grader draws the ratio of area perfused to the total
area graded, the concentric rings method utilizes a set template. It has a perfect
agreement with the ischemic index method, a higher inter-grader agreement, and
a shorter grading time19. Using the concentric rings method, it was observed that
at 12 and 24 months post laser, PRP laser resulted in a significant increase in
the perfusion of the eye while the control eyes showed no change. These results
suggest that the changes in ischemia are most likely the result of the laser
treatment.
When analyzing the optic nerve, both OCT and HRT testing showed a
similar trend. In the vertical C/D ratio on the OCT, there was a slight increase of
+0.009 at 6, 12, and 24 months compared to baseline in the PRP laser group.
The HRT showed an increase in the vertical C/D ratio by +0.06 post- 6 months.
There was a statistically significant decrease in pressure by 1.5 mm Hg at 6
months compared to baseline (18.81 ± 4.04 mm Hg) (Figure 2.5)32. IOP
remained lowered before recovering to 18.25 ± 3.98 mm Hg at 24 months.
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The current gold standard for analyzing the optic nerve is grading of
stereo-photographs by glaucoma specialists. Two glaucoma specialists were
assigned to grade over 24 months, whereas grader 2 indicated a significant
increase at 6 and 12 months, with a further significant increase at 24 months
post-laser. There is a discrepancy between the grading of the optic nerves postlaser treatment by ophthalmologists. This has been shown in other studies of
disc analysis and it is apparent that a more objective analysis is needed33, 34. To
verify whether the discrepancy is due to the laser treated eyes and not the
graders themselves, the graders also assessed control eyes of diabetic patients
not requiring laser treatment. When asked to grade the control eyes, both grader
1 and 2 found that over 24 months, there was no significant difference in the C/D
ratios. This discrepancy between the graders and OCT/HRT testing data
suggests that non-morphological changes in the colour of the optic nerve postPRP result in a decreased ability to consistently grade nerves for cupping which
is important in recognizing the potential for hidden glaucoma.
In addition to the inconsistent clinical grading of the optic nerve post-laser,
visual acuity showed a non-significant decline and visual fields showed a
progressive significant decline at 12 and 24 months post-laser. It has been
shown in a past study done by Hudson et al. that in diabetic macular edema
patients, laser photocoagulation results in a perimetric sensitivity loss within 10°
of the fovea despite showing visual acuity stabilization35. Visual fields and
electroretinography have been performed on diabetic retinopathy patients postlaser treatments and have demonstrated that roughly 40% of the peripheral
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retina is destroyed by photocoagulation resulting in visual field defects.5 A study
by Subush et al. has also documented a mild loss of retinal sensitivity 6 months
post-laser treatment36. These past studies have reported the degree of peripheral
retina destroyed by photocoagulation; however, none have studied progressive
long-term visual field loss over a two year time period5, 35, 36. With the unreliable
grading of the optic nerve and further progressive deterioration of visual fields
post-laser, it is understandable why some diabetic patients post-PRP are being
misdiagnosed as having normal-tension glaucoma despite the likelihood that the
presenting symptoms can be attributed to iatrogenic effects of the laser.
One limitation of the current study is that despite meeting the power
number calculations for the treatment group, 16 control patients in the study
would have been preferred. Although the number of participants for the control
group did not meet the limit, the control group did not show any significant
difference in any of the testing and showed stable trends. As both glaucoma and
the effects of PRP on RNFL and optic disk are often progressive, the idea of
extending the follow up period beyond 2 years to increase the ability to discern
small, yet progressive changes is enticing. It would be interesting to determine if
there are any predictive factors that can indicate which patients who receive PRP
will progress and what the rate of that progression will be.
Studies have previously reported short-term visual field changes following
PRP but no study has looked at the progressive nature over a two year time
period5, 36. The progressive improvement in ischemia following PRP is also a
novel finding. Studies have never correlated changes in visual fields with optic
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nerve changes post-PRP. For that reason, the current study sought to obtain
comprehensive results and conducted analyses of the optic nerve with both
structural and functional tests to see if any early changes could be found in the
optic nerve post-PRP.
In conclusion, the current study has found that pascal photocoagulation
did not cause significant changes to macular or RNFL thickness over the 24
month time period. The morphology of the optic nerve head appeared unchanged
following laser treatment as observed on the OCT and HRT diagnostic machines.
Despite an improvement in peripheral perfusion, there was a significant
progressive decline of peripheral visual field over the study period. Clinical
grading of the optic nerve was more unreliable following PRP despite the
absence of significant morphological changes as detected by the OCT and HRT
diagnostic machines. Additional research is needed to help guide clinicians in
making a diagnosis of normal tension glaucoma in diabetic patients who have
received PRP.
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Chapter 3

3

Two-year analysis of structural and functional changes
to the retina and optic nerve following anti-VEGF
treatments for diabetic macular edema patients

The chapter addresses specific objectives outlined in aim 3:
3. To describe the effects of anti-VEGF injections and the frequency of
injections on the structural and functional changes to the retina and optic
nerve of DR patients with underlying DME using in vivo clinical
pathological analysis.
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3.1 Introduction
Diabetic macular edema (DME) is a common complication of diabetic
retinopathy (DR). During DR, chronic hyperglycemia results in enhanced
production of vascular endothelial growth factors (VEGF), advanced glycation
end products, nitric oxide, oxidative stress and inflammation1. The
aforementioned factors disrupt the blood retinal barrier (BRB), increasing
permeability, causing interstitial fluid accumulation and the development of
DME2. Inhibition of these factors can reduce the development of fluid-filled cysts.
At the present time, the gold standard, first line of treatments clinically used to
treat DME patients are intravitreal anti-VEGF injections3.
Over the past decade, there have been increased clinical reports of
diabetic patients receiving anti-VEGFs developing signs of glaucoma and optic
neuropathy. Diabetes is a risk factor for the development of glaucoma and the
use of anti-VEGFs might augment the risk4. Past studies have analyzed the
safety of intravitreal anti-VEGF injections in age-related macular degeneration
(AMD) but none have examined the effects of the treatments on the optic nerve526

. Studies have also reported a sustained increase in intraocular pressures (IOP)

following intravitreal injections of anti-VEGFs in AMD patients27-31. With the
continued and increased use of anti-VEGF, numerous questions have been
raised in regards to whether they have a role in increasing the risk of developing
glaucoma and what are the long-term effects of the IOP spikes27, 32. The results
of controlled trials that look at visual acuity and central macular thickness as well
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as retinal and optic nerve structures are greatly needed to substantiate the safety
and efficacy of anti-VEGF drugs for DR with underlying DME.
The purpose of the following study was to determine whether the use of
ranibizumab (Lucentis), an anti-VEGF, results in structural and functional
changes to the retina and optic nerve of DR patients with underlying DME over a
two year time period. This is the first comprehensive study to investigate the
long-term structural and functional effects of anti-VEGF treatments on the retina
and optic nerve that involve the analysis of macular thickness, the retinal nerve
fiber layer (RNFL), mean perfusion, vertical C/D ratio, cup volume, stereo photos,
IOP, visual acuity and visual fields.
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3.2 Methods
The prospective study was conducted at the Ivey Eye Institute in London,
Ontario, Canada. Ivey Eye Institute is a tertiary care academic center. The study
was approved by Health Sciences Research Ethics Board of Western University
and complies with the Declaration of Helsinki. Prospective, treatment- naïve
diabetic patients with at least one eye having clinically significant diabetic
macular edema (central macular thickness >300 μm) according to the ETDRS
guidelines and requiring intravitreal anti-VEGF injections were recruited into the
study. Participants were over the age of 18 years. Participants were excluded
from the study if they had prior intravitreal anti-VEGF injections, advanced lens
opacity, cataracts that could affect diagnostic testing, history of glaucoma, any
other disorder of the optic nerve (optic neuropathy, neuritis, uveitis or retinal
degeneration), presence/development of proliferative disease and prior retinal
treatment (PRP, focal laser or surgery within 6 months of participation). All
participants provided informed consent. Diabetic patients who did not have
clinically significant macular edema and did not require anti-VEGF treatment or
other retinal treatments were chosen as control. Participants were evaluated at
pre-injection baseline and at 6, 12, and 24 months post-baseline. During each
study visit, participants underwent optical coherence tomography (OCT), visual
field (VF) and intravenous fluorescein angiography (IVFA) testing as well as a
standard ophthalmic exam which included best-corrected Snellen visual acuity
(BCVA), intraocular measurement using Goldmann applanation tonometer, and
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slip lamp examination. Humphrey 24-2 SITA visual field testing was performed
with undilated eyes. .

3.2.1

Optical Coherence Tomography
Measurement of the macula and optic nerve through the macular

thickness, optic disc cube and HD 5 line raster imaging tests were performed
with the optical coherence tomography (Cirrus HD-OCT 4000, Carl Zeiss
Meditech, Dublin, California). The principles and protocol have been previously
described in detail33, 34, 35. OCT tests were taken at pre-injection baseline and at
6, 12, and 24 months post-baseline. The scan at each time of measurement was
repeated 3 times to ensure highest signal strength.
The macula was analyzed by a 6 x 6 mm scan and a resolution of 512 x
128 (128 horizontal scan lines consisting of 512 A-scans). The macular thickness
was displayed as 3 concentric circles, the central circular subfield being 1 mm in
diameter, the inner ring being 3 mm in diameter and the outer ring being 6 mm in
diameter. Each ring was divided into superior, inferior, nasal, and temporal
quadrants7. When performing a scan of the optic nerve, a 3.4 mm ring was
centered on the optic nerve and 768 A-scans were performed36, 37. The average
RNFL thickness, vertical C/D ratio, and cup volume were measured. To analyze
images of the retinal structure, a HD 5 line raster was performed. This highdensity scan does 4,096 A-scans in five planes to provide a high definition
image37.
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3.2.2

Humphrey Visual Field Analyzer
To measure peripheral visual fields, standard Humphrey 24-2 SITA testing

algorithm was performed on Humphrey Field Analyzer, model 750i (Zeiss
Humphrey Systems, Dublin, CA, USA). In the 24-2 SITA testing algorithm, 54
individual points are tested. From those points, the threshold values were
calculated and compared to a normative database for similar aged normalsighted individuals38, 39. Participants that had false positive responses greater
than 15%, fixation losses and false negative responses greater than 20% were
excluded from the study38.

3.2.3

Wide-Field Fluorescein Angiogram and Quantification of
Ischemia
Wide-field fluorescein angiography was performed on the Optos 200 Tx

with an intravenous injection of 5 ml of 10% sodium fluorescein40. Intravenous
fluorescein angiography (IVFA) photos and digital stereoscopic photographs
were taken. To quantify the amount of ischemia in each patient, the best IVFA
image obtained during the arteriovenous phase was used. For analysis, the
uncompressed tiff images were transferred from the Optos V2 Vantage Review
Software to Adobe software (Adobe Systems, Inc, San Jose, CA).
Two graders that were masked to the study quantified the amount of
ischemia in each patient by using the concentric rings method which has been
previously described in detail41. In this method, the innermost circle was first
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centered on the optic nerve to be sized proportionately and then repositioned to
be fovea-centered. The 12 segments in each of the rings were graded as,
“perfused” or “non-perfused” if more than 50% of the segment showed either a
perfused or non-perfused morphology. The classification of “non-perfused” and
“perfused” morphology was taken from the SCORE study. In the control and antiVEGF injected eyes, “non-perfused” was characterized by a darker appearance
of the retina and pruned tree appearance (narrowed and difficult to see) of
surrounding arterioles. “Perfused” morphology was characterized by its clear
ground-glass opacity42. Calculations of the mean perfused ratio were performed
using the mean perfusion ratio = area perfused / (area perfused + non-perfused).
Each segment in each of the rings was given a value of either 0 indicating nonperfused or 1 indicating perfused retina.

3.2.4

Optic Nerve Grading
Stereoscopic photographs were taken with Optos 200 Tx at baseline, 6,

12, and 24 months post-baseline injection. Photographs were cropped to a size
of 4 x 4 mm for optic nerve grading. Two glaucoma specialists independently
graded the cup-to-disk (C/D) ratio of the anti-VEGF injected eyes and control
eyes of diabetic patients not requiring injections. The graders were masked to the
type of patients and purpose of the study.
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3.2.5

Ranibizumab (Lucentis) Injections
During the induction phase, participants received monthly intravitreal

injections of ranibizumab (Lucentis, 0.5 mg in 0.05 mL solution for injection;
Novartis Pharmaceuticals Canada Inc., Quebec, Canada) for 3 months. Post 3
months, participants received injections on an as needed basis until they were
clinically stable based on their OCT tests and clinical assessment. Ranibizumab
treatment was reinitiated if BCVA decreased by 5 letters or if central macular
thickness became greater than 300 μm.
Patients received injections in clinical rooms. Topical anesthesia was
administered and the eye was disinfected with povidone iodine eye drops. An
ophthalmic speculum was utilized to retract the eye lid. A 30 gauge needle was
used to administer the intravitreal anti-VEGF injection 3.5-4.0 mm posterior to the
limbus.

3.2.6

Statistical Analysis
Data was analyzed using GraphPad Prism 5 (GraphPad Software, La

Jolla, CA, USA). Snellen best-corrected visual acuity (BCVA) measurements
were converted to logarithm of the minimum angle of resolution (logMAR) scores
for statistical analysis. To compare the average age of the patients, an unpaired
t-test was performed and to compare the percentage of female participants
between control and anti-VEGF groups, a fisher’s exact test was used. To
compare the differences at specified points over time in the anti-VEGF and
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control groups, the paired t-test was performed. To statistically analyze the
interval changes of measurements in the anti-VEGF and control groups at
baseline, 6, 12, and 24 months, respectively, repeated measures ANOVA with a
Bonferroni's multiple comparisons test was used. ANOVA with Bonferroni method
was performed as outlined in J Neter, W Wasserman, and MH Kutner, Applied
Linear Statistical Models, 3rd edition, Irwin, 1990. All data was expressed as
mean ± SD and accepted as statistically significant if p<0.05. A correction of
p<0.017 was applied for the Bonferroni's multiple comparison test.
To calculate the sample size with an overall power of 80%, p<0.05 was
used as an acceptable significance level. Using a two-tailed test for a control
with an optic nerve of size 0.3 and an atrophy group of size 0.6, both derived
from cup/disk ratio, the effect size would be 0.3. Adding the values to the sample
size calculation, it was calculated that 16 patients would be needed for an 80%
power number. Thirty-six diabetic patients requiring anti-VEGF injections were
recruited into the study but four were removed due to patient compliance and two
for developing proliferative disease and requiring PRP treatment. Twenty-one
patients were used as diabetic controls not requiring anti-VEGF injections. The
diabetic control group did not have proliferative disease that developed during
the two year study period. The control was included to ensure that the observed
changes could be correlated with the anti-VEGF treatments and not due to
diabetic disease itself.
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3.3 Results
A single eye from each of the 30 patients requiring anti-VEGF injections
and 21 control patients not requiring anti-VEGF injections, who were recruited
between September 11, 2014 and July 23, 2015, was analyzed. The average age
of patients was 67.7 ± 7.5 years for the control group and 63.9 ± 6.8 years for the
anti-VEGF group. The control group had 33.3% female participants while the
anti-VEGF group had 43.3% female participants. The control and anti-VEGF
groups did not significantly differ (p>0.05) in any of these categories (Table 3.1).
None of the patients developed proliferative diabetic retinopathy during the study.
Patients received a mean ± standard deviation of 9.6 ± 5.3 injections ranging
from 4 to 22 injections.
Following anti-VEGF treatment, the macular thickness (Figure 3.1A)
significantly decreased by 27.9 µM at 6 months (313.60 ± 39.87 µM, p=0.0002)
relative to baseline (341.50 ± 55.33 µM). The macular thickness further
decreased to 309.80 ± 33.80 µM at 12 months (p=0.0001) and 303.40 ± 32.16
µM at 24 months (p=0.0001). Compared to baseline (287.70 ± 29.36 µM), the
control group showed no significant change in macular thickness at 6 months
(286.70 ± 27.83 µM, p=0.51), 12 months (289.40 ± 31.84 µM, p=0.51), or 24
months (288.20 ± 32.89 µM, p=0.84).
RNFL thickness (Figure 3.1B) significantly decreased at 6 months (90.03
± 14.40 µM, p=0.0005), 12 months (87.97 ± 12.76 µM, p=0.0001) and 24 months
(87.47 ± 11.81 µM, p=0.0001) compared to baseline (98.37 ± 18.89 µM). The
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Table 3.1. Demographics of patients involved in the study.

Control

anti-VEGF

P-Value

Number of eyes

21

30

-

Average age
(years± SD)

67.7 ± 7.5

63.9 ± 6.8

0.07*

Female
Participants (%)

33.3%

43.3%

0.57†

Mean anti-VEGF
injections ±
standard
deviation

-

9.6 ± 5.3

-

Table 4*Unpaired t-test
†Fisher’s exact test
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Figure 3.1. Interval changes in (A) macular thickness, (B) RNFL thickness and
(C) mean perfused ratio at baseline, 6, 12, and 24 months in the control and antiVEGF groups. p-value: control group differences between baseline and follow-up
measurements, paired t-test. p'-value: anti-VEGF group differences between
baseline and follow-up measurements, paired t-test.
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Figure 21 Interval changes in (A) macular thickness, (B) RNFL thickness and (C)
mean perfused ratio at baseline
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control group had no significant change in RNFL thickness at 6 months (84.00 ±
14.94 µM, p=0.75), 12 months (83.19 ± 13.42 µM, p=0.35), or 24 months (83.10
± 13.73 µM, p=0.42) compared to baseline (84.33 ± 15.51 µM). Analyzing each
region, there was no significant difference in thickness in the superior, inferior,
temporal and nasal regions of the RNFL for the control group but a significant
decrease in all regions for the anti-VEGF group (p < 0.02) (Table 2).
The mean perfused ratio showed a significant improvement at 6 months
(0.65 ± 0.09, p=0.0005), 12 months (0.67 ± 0.10, p=0.0001) and 24 months (0.67
± 0.09, p=0.0001) compared to baseline (0.62 ± 0.09) for the anti-VEGF group.
(Figure 3.1C). There was no significant difference in the control group at 6
months (0.60 ± 0.11, p=0.33), 12 months (0.60 ± 0.11, p=0.33) or 24 months
(0.60 ± 0.11, p=0.86) compared to baseline (0.60 ± 0.11).
Analysis of the optic nerve and the associated cup volume by OCT (Figure
3.2) showed a significant increase at 6 (0.094 ± 0.10, p=0.02), 12 (0.096 ± 0.10,
p=0.007), and 24 months (0.095 ± 0.10, p=0.03) compared to baseline (0.089 ±
0.1). Cup volume remained consistent and showed no significant difference in
the control group at 6 (0.110 ± 0.13, p=0.09), 12 (0.111 ± 0.13, p=0.56), and 24
months (0.116 ± 0.13, p=0.86) compared to baseline (0.115 ± 0.13).
Vertical C/D ratio by OCT (Figure 3.3) showed a significant increase at 6
months (0.42 ± 0.20, p=0.0014), 12 months (0.43 ± 0.19, p=0.0009) and 24
months (0.44 ± 0.18, p=0.0009) compared to baseline (0.39 ± 0.21). Vertical C/D
ratio remained consistent in the control group, being 0.47 ± 0.24 at baseline, 0.47
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Table 3.2. Changes in RNFL thickness (µm) over the course of 24 months in the
control and anti-VEGF groups.
Baseline

6 months

12 months

24 months

PValue*

Average
Control
anti-VEGF

84.33 ± 15.51
98.37 ± 18.89

84.00 ± 14.94
90.03 ± 14.40

83.19 ± 13.42
87.97 ± 12.76

83.10 ± 13.73
87.47 ± 11.81

0.61
0.0001

Superior
Control
anti-VEGF

99.52 ± 24.43
113.50 ± 18.85

99.86 ± 23.57
109.10 ± 21.04

97.43 ± 23.13
107.00 ± 19.49

96.05 ± 21.47
104.90 ± 18.14

0.54
0.0001

Inferior
Control
anti-VEGF

103.10 ± 22.61
122.60 ± 33.94

101.60 ± 20.94
111.00 ± 19.89

101.00 ± 19.45
108.30 ± 18.29

101.00 ± 19.28
107.80 ± 17.80

0.63
0.0001

Temporal
Control
anti-VEGF

63.05 ± 12.36
80.07 ± 25.74

64.81 ± 11.82
67.07 ± 14.09

63.57 ± 11.75
66.20 ± 13.16

64.43 ± 14.65
66.83 ± 14.30

0.64
0.0001

Nasal
Control
anti-VEGF

71.90 ± 15.92
77.73 ± 16.15

69.76 ± 14.91
73.10 ± 15.84

70.76 ± 12.45
70.27 ± 12.80

69.86 ± 13.47
69.93 ± 12.64

0.50
0.0001

Table 5 RNFL = retinal nerve fiber layer
*Repeated Measures ANOVA
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Figure 3.2. Interval changes in cup volume measured on the OCT at baseline, 6,
12, and 24 months in the control and anti-VEGF groups. p-value: control group
differences between baseline and follow-up measurements, paired t-test. p'value: anti-VEGF group differences between baseline and follow-up
measurements, paired t-test.
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Figure 22 Interval changes in cup volume measured on the OCT at baseline, 6, 12,
and 24 months in the

OCT
Cup volume (mm3)

0.20
p=0.09

0.15

p=0.56

p=0.86

**

p'=0.03

0.10
0.05

*

p'=0.007

6

12

p'=0.02

*

0.00
0

24

Time of Measurement (Months)

Control
anti-VEGF

152

Figure 3.3. Interval changes in vertical cup/disk ratio measured on the OCT at
baseline, 6, 12, and 24 months in the control and anti-VEGF groups. p-value:
control group differences between baseline and follow-up measurements, paired
t-test. p'-value: anti-VEGF group differences between baseline and follow-up
measurements, paired t-test.

153

Figure 23 Interval changes in vertical cup/disk ratio measured on the OCT at
baseline, 6, 12, and 24
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± 0.22 at 6 months (p=0.95), 0.47 ± 0.22 at 12 months (p=0.92) and 0.54 ± 0.23
at 24 months (p=0.86). When assessing participants receiving less than 10
injections (n=15) and those that received 10 or more injections (n=15),
participants that received 10 or more injections showed a significant increase in
the vertical C/D ratio at 6 months (0.48 ± 0.16, p=0.03), 12 months (0.49 ± 0.14,
p=0.01) and 24 months (0.50 ± 0.14, p=0.002) compared to baseline (0.44 ±
0.18) (Figure 3.4). Participants that received less than 10 injections showed a
non-significant increase in the vertical C/D ratio at 6 months (0.36 ± 0.22,
p=0.10), 12 months (0.37 ± 0.22, p=0.08) or 24 months (0.38 ± 0.21, p=0.07)
compared to baseline (0.33 ± 0.23).
Two glaucoma specialists were assigned to independently grade the
vertical C/D ratios in the same eyes that received anti-VEGF injections using
stereo photographs (Figure 3.5A). Both grader 1 and 2 indicated there was a
significant increase in the vertical C/D ratio over the course of 2 years. At
baseline, the mean vertical C/D was 0.309 ± 0.17 and grader 1 noted an increase
at 6 months (0.320 ± 0.16, p=0.06), with a further significant increase at 12
months (0.322 ± 0.17, p=0.03) and 24 months (0.324 ± 0.17, p=0.03). Grader 2
indicated baseline mean vertical C/D ratio of 0.309 ± 0.11 and noted a significant
increase at 6 months (0.338 ± 0.11, p=0.02), with a further increase at 12 months
(0.353 ± 0.12, p=0.005) and 24 months (0.379 ± 0.14, p=0.0006). The graders
also graded control eyes of diabetic patients not requiring anti-VEGF treatment.
Both grader 1 and 2 found that over 24 months, there was no significant
difference (p ≥ 0.17) (Figure 3.5B).
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Figure 3.4. Interval changes in vertical cup/disk ratio measured on the OCT at
baseline, 6, 12, and 24 months in participants receiving less than 10 injections
and 10 or more injections. p-value: differences between baseline and follow-up
measurements of participants receiving less than 10 injections, paired t-test. p'value: differences between baseline and follow-up measurements of participants
receiving 10 or more injections, paired t-test.
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Figure 24 Interval changes in vertical cup/disk ratio measured on the OCT at
baseline, 6, 12, and 24
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Figure 3.5. Interval changes in vertical cup/disk ratio measured by two masked
glaucoma specialists using stereo photographs at baseline, 6, 12, and 24 months
in the (A) anti-VEGF group and the (B) control group. p-value: grader 1
differences between baseline and follow-up measurements, paired t-test. p'value: grader 2 differences between baseline and follow-up measurements,
paired t-test.
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Figure 25 Interval changes in vertical cup/disk ratio measured by two masked
glaucoma specialists
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Visual field tests had an average baseline mean deviation (MD) (Figure
3.6A) in the anti-VEGF group of -2.37 ± 3.72 dB. Mean deviation improved at 6
months by 0.72 dB (-1.65 ± 4.06 dB, p=0.052) but returned to baseline levels by
12 months (-2.40 ± 4.42 dB, p=0.93) and worsened by 24 months (-3.01 ± 4.50,
p=0.10). The control group showed no significant differences in visual field MD at
baseline (-3.85 ± 6.38 dB), 6 months (-3.65 ± 5.52 dB, p=0.71), 12 months (-3.76
± 4.93 dB, p=0.89), and 24 months (-4.22 ± 5.60 dB, p=0.54). Baseline mean
best-corrected visual acuities (Figure 3.6B) were 0.24 ± 0.19 logMAR in the
control group and 0.53 ± 0.35 logMAR in the anti-VEGF group. Visual acuity
significantly improved to 0.34 ± 0.17 logMAR at 6 months (p=0.0006) and
maintained this improvement, being 0.34 ± 0.22 logMAR at 12 months
(p=0.0001) and 0.33 ± 0.15 logMAR at 24 months (p=0.0006). Visual acuity
remained consistent in the control group, being 0.24 ± 0.19 logMAR at baseline,
0.25 ± 0.19 logMAR at 6 months (p=0.59), 0.24 ± 0.19 logMAR at 12 months
(p=0.69) and 0.25 ± 0.20 logMAR at 24 months (p=0.45). The changes were not
statistically significant.
In the anti-VEGF group, intraocular pressure (IOP) remained consistent
over the two-year time period (Figure 3.7). At baseline, it was 16.57 ± 2.89
mmHg and slightly decreased to 16.53 ± 3.33 mmHg at 6 months (p=0.96). At
12 months (p=0.94), it was at 16.60 ± 3.09 mmHg and remained constant by 24
months (16.63 ± 3.09 mmHg, p=0.91). In the control group, IOP remained
constant, being 16.67 ± 2.87 mmHg at baseline, 16.52 ± 3.19 mmHg at 6 months
(p=0.82), 16.43 ± 2.93 mmHg at 12 months (p=0.63) and 16.52 ± 3.67 mmHg at
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24 months (p=0.85). The changes were not statistically significant.
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Figure 3.6. Interval changes in mean deviation measured on the (A) Humphrey
Visual Field Analyzer and (B) visual acuity at baseline, 6, 12, and 24 months in
the control and anti-VEGF groups. p-value: control group differences between
baseline and follow-up measurements, paired t-test. p'-value: anti-VEGF group
differences between baseline and follow-up measurements, paired t-test.
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Figure 26 Interval changes in mean deviation measured on the (A) Humphrey
Visual Field Analyzer
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Figure 3.7. Interval changes in intraocular pressure at baseline, 6, 12, and 24
months in the control and anti-VEGF groups. mmHg= millimeter of mercury. pvalue: control group differences between baseline and follow-up measurements,
paired t-test. p'-value: anti-VEGF group differences between baseline and followup measurements, paired t-test.
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Figure 27 Interval changes in intraocular pressure at baseline, 6, 12, and 24 months
in the control
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3.4 Discussion
The 24 month results from the study demonstrate that during anti-VEGF
therapy, the macular thickness significantly decreased by 6 months and, while
the patients were undergoing therapy, remained lowered over a 24 month time
period. Mean BCVA improved by roughly 4 lines of vision at 6 months and the
improvement was maintained over a 24 month period of undergoing therapy.
The results were expected and coincide with previously published anti-VEGF
landmark studies43-50. The RESTORE study demonstrated that ranibizumab
monotherapy alone, or when combined with a laser treatment, is more effective
in improving BCVA than only undergoing the laser treatment and, overall, the
health-related quality of life is improved48. The RISE and RIDE studies have
shown that, compared to sham injections, intravitreal injections of ranibizumab
(Lucentis) improve BCVA and decrease macular thickness caused by edema50.
The landmark studies have cemented anti-VEGF therapy as the standard of care
for DME treatment. In all instances of anti-VEGF therapy, VEGF is blocked in the
diabetic eye, reducing blood vessel proliferation and leakage. If the leakage is
centralized within the macula, anti-VEGF therapy reduces macular edema,
decreasing the overall macular thickness and in turn improving central vision.
To determine whether anti-VEGF therapy in DME patients results in retinal
reperfusion, the amount of ischemia was quantified using the mean perfused
ratio. According to the analysis of fluorescein angiography photographs from the
RISE and RIDE trials, patients receiving sham injections, as compared to those
receiving ranibizumab, had faster progression of retinal nonperfusion51. The
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mean perfused ratio was calculated by the concentric rings method which has
been previously utilized by Nicholson et al41. Compared to the standard ischemic
index method, wherein the grader draws the ratio of area perfused to the total
area graded, the concentric rings method utilizes a set template. The method has
a perfect agreement with the ischemic index method, a higher inter-grader
agreement, and a short-grading time41. Using the concentric rings method, there
was a significant increase in perfusion of patients in the anti-VEGF group up until
12 months. The increased level of perfusion remained unchanged when
measured at 24 months. The control eyes showed no change in perfusion.
These results correlate with those of a past study which examined anti-VEGF
reperfusion in diabetic retinopathy patients within 5 months of having an
injection52. That study used standard grading of the reperfusion and quantified
using ImageJ software. Roughly 75% of the patient’s demonstrated reperfusion52.
With a higher sample size, longer time-frame, and a different method of
analyzing perfusion, our results verify the previous findings. The results suggest
that although diabetes remains a contributing factor, the improvement in the
degree of ischemia is most likely a result of the anti-VEGF treatment through the
stabilization of blood vessels and other unknown mechanisms.
The average RNFL thickness measured from the start of anti-VEGF
treatment, significantly decreased over a 24-month time period. Analyzing each
quadrant separately, the superior, inferior, temporal, and nasal regions of the
RNFL all showed significant decrease over a 24-month time period in patients
undergoing anti-VEGF therapy but not in control patients. The greatest observed
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change in thickness occurred within the first 6 months. Up until the 6 month
period, anti-VEGF treatments are often administered monthly until the patient
becomes clinically stable and then receives injections on an as needed basis. A
recent study has examined RNFL thickness in diabetic patients in comparison to
normal controls. Despite diabetics having a thinner RNFL compared to normal
controls, there was no significant reduction of RNFL thickness in both groups
over a two-year follow-up period53. Past studies have examined patients affected
with age related macular degeneration (AMD). The studies report that patients
undergoing long-term anti-VEGF therapy have a decreased retinal ganglion cell
layer when compared to the untreated eye but show no change in RNFL
thickness54, 55. Due to the nature of the disease, people with diabetes are more
sensitive to ocular changes than AMD patients and no other study has examined
RNFL or optic nerve in DME patients undergoing anti-VEGF therapy.
The parapapillary RNFL is used as a surrogate measurement of the optic
nerve status. When analyzing the optic nerve with OCT, the cup volume
significantly increased over a 24-month time period in DME patients undergoing
anti-VEGF therapy. The vertical C/D ratio also significantly increased by +0.06
over the time period. This is the first study to analyze the effects of anti-VEGF
therapy on the optic nerve. No optic nerve edema was present in any of the
patients as visualized by OCT. When assessing participants that received less
than 10 anti-VEGF injections and patients that received 10 or more injections,
participants that received 10 or more injections showed a significant increase in
the vertical C/D ratio by +0.064 over the 24 month time period. Participants that
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received less than 10 injections had a non-significant increase of +0.054 in the
vertical C/D ratio. There was no significant difference (p=0.16) in baseline vertical
C/D ratios between the two groups despite participants that had less than 10
injections having a mean baseline vertical C/D ratio of 0.33 ± 0.23 and
participants that had 10 or more injections having a mean baseline vertical C/D
ratio of 0.44 ± 0.18.
To eliminate scanning error or results being influenced by the repeatability
or reproducibility of the OCT, the vertical C/D ratios were graded by glaucoma
specialists using stereo-photographs, which is the current gold standard for
analyzing the optic nerve. Two glaucoma specialists, that were masked to the
study, were assigned to grade the vertical C/D ratio in the same eyes following
anti-VEGF treatment using stereo photographs. Similarly to the OCT results, both
grader 1 and 2 indicated that there was a significant vertical C/D ratio increase
over 12 months with grader 2 stating a further significant increase at 24 months.
Grader 1 indicated there was a +0.02 increase in the vertical C/D ratio whereas,
grader 2 indicated there was a +0.07 increase in the vertical C/D ratio over the
course of 24 months. Even though there was a discrepancy in the grading
method of the optic nerves by the two ophthalmologists, both graders indicated a
significant increase in the C/D ratio during anti-VEGF therapy. The discrepancy
has been observed in other studies of disc analysis suggesting that a more
objective analysis is needed56, 57. To confirm that the observed changes were due
to the anti-VEGF therapy and not the graders themselves, the graders also
assessed control eyes of diabetic patients not requiring anti-VEGF treatment.
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Both grader 1 and 2 have found that over 24 months, there was no significant
difference in the C/D ratios. The data combined with OCT results suggests that
there are morphological changes that happen to the optic nerve in DME patients
under anti-VEGF therapy which are not caused by glaucoma.
Overall, in regards to IOP results, there was no significant difference that
occurred in patients over a 24-month treatment time frame. Mean IOP at baseline
was 16.57 mmHg and 16.63 mmHg at 24 months. Past studies have shown
conflicting results on whether or not long-term anti-VEGF usage results in
sustained increase in IOP58, 59. In the current study, that examined DME patients
undergoing ranibizumab treatment for 24 months, no sustained increase in IOP
was observed. Functionally, looking at the effects of anti-VEGF therapy on
peripheral vision, visual field testing showed no significant difference. It is
important to note from baseline to 6 months, visual fields slightly improved by
0.72 dB but from 6 months to 24 months, peripheral vision declined by -1.36 dB.
Previous studies have confirmed that structural changes in the retina
precede functional changes60, 61, 62. Although this is the longest study of its kind,
we feel that analyzing patients over 24-months might not have been sufficient
and thus, the time frame has limited the ability to detect more minute changes to
the retina. In order to determine whether or not the effects of anti-VEGF therapy,
as observed on RNFL, optic disk and ultimately peripheral vision, are indeed
progressive and cause optic neuropathy, it would be enticing to extend the follow
up period beyond 2 years. The next step would be to conduct a multi-center
study analyzing common anti-VEGFs such as ranibizumab, bevacizumab and
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aflibercept. While sharing the same basic mechanism, anti-VEGFs all have
different molecular characteristics, which cause differences in potency, systemic
clearance, and systemic VEGF inhibition50, 63. It would be valuable to determine
whether higher affinity anti-VEGFs result in greater changes to the optic nerve as
well as if any predictive factors affect the changes to the optic nerve in regards to
progress and the rate.
This is the first study to analyze long-term structural and functional
changes to the retina and optic nerve in DME patients undergoing anti-VEGF
therapy. As such, the current study sought to obtain comprehensive results. The
analyses of the optic nerve included both structural and functional tests, and
grading of stereo photographs by glaucoma specialists to detect any early
changes in the optic nerve in patients starting anti-VEGF treatments.
In conclusion, anti-VEGF therapy may potentially be detrimental to the
optic nerve by decreasing RNFL thickness, increasing cup volume and
increasing vertical cup/disk ratio over time as measured on OCT and through
grading of stereo photographs by glaucoma specialists. Patients that received 10
or more injections had a significant increase in the vertical C/D ratios compared
to the patients that received less than 10 injections. Despite an improvement in
peripheral perfusion, there was a slight decline of peripheral visual fields from 6
to 24 months in DME patients undergoing anti-VEGF therapy. The results
provide a cautionary note to monitor both the retina and optic nerve status in
patients undergoing frequent anti-VEGF injections.

171

3.5 References
1.

Kaur C, Foulds W, Ling E. Blood-retinal barrier in hypoxic ischaemic
conditions: basic concepts, clinical features and management. Progress In
Retinal And Eye Research 2008;27(6):622-647.

2.

Porte D, Sherwin RS, Baron A, Ellenberg M, Rifkin H. Ellenberg & Rifkins
diabetes mellitus. New York: McGraw-Hill, Medical Pub. Division; 2003.

3.

Holt RIG, Cockram CS, Flyvbjerg A, Goldstein BJ. Textbook of diabetes.
4th ed. Chichester, West Sussex, UK: Wiley Blackwell; 2010.

4.

Diabetes and Your Eyesight. Diabetes and Your Eyesight | Glaucoma
Research Foundation. http://www.glaucoma.org/glaucoma/diabetes-andyour-eyesight.php. Accessed May 16, 2017.

5.

Osaadon P, Fagan XJ, Lifshitz T, Levy J. A review of anti-VEGF agents
for proliferative diabetic retinopathy. Eye (Lond) 2014;28(5):510-520.

6.

Simó R, Hernández C. Intravitreous anti-VEGF for diabetic retinopathy:
hopes and fears for a new therapeutic strategy. Diabetologia
2008;51(9):1574-1580.

7.

Hernández C, Simó R. Strategies for blocking angiogenesis in diabetic
retinopathy: from basic science to clinical practice. Expert Opin Invest
Drugs 2007;16:1209-1226

172

8.

Spaide RF, Fisher YL. Intravitreal bevacizumab (Avastin) treatment of
proliferative diabetic retinopathy complicated by vitreous hemorrhage.
Retina 2006;26:275-278.

9.

Oshima Y, Sakaguchi H, Gomi F, Tano Y. Regression of iris
neovascularization after intravitreal injection of bevacizumab in patients
with proliferative diabetic retinopathy. Am J Ophthalmol 2006;142:155158.

10.

Chen E, Park CH (2006) Use of intravitreal bevacizumab as a
preoperative adjunct for tractional retinal detachment repair in severe
proliferative diabetic retinopathy. Retina 2006;26:699-700.

11.

Avery RL, Pearlman J, Pieramici DJ, Rabena MD, Castellarin AA, Nasir
MAA et al. Intravitreal Bevacizumab (Avastin) in the Treatment of
Proliferative Diabetic Retinopathy. Ophthalmology 2006;113(10):e1-15.

12.

Jorge R, Costa RA, Calucci D, Cintra LP, Scott IU. Intravitreal
bevacizumab (Avastin) for persistent new vessels in diabetic retinopathy
(IBEPE study). Retina 2006;26:1006-1013.

13.

Arevalo JF, Wu L, Sanchez JG, Maia M, Saravia MJ, Fernandez CF.
Intravitreal bevacizumab (avastin) for proliferative diabetic retinopathy: 6months follow-up. Eye (Lond) 2007;23(1):117-123.

173

14.

Ishikawa K, Honda S, Tsukahara Y, Negi A. Preferable use of intravitreal
bevacizumab as a pretreatment of vitrectomy for severe proliferative
diabetic retinopathy. Eye (Lond) 2007;23(1):108-111.

15.

Cunningham ET Jr1, Adamis AP, Altaweel M, Aiello LP, Bressler NM,
D'Amico DJ et al. A Phase II randomized double-masked trial of
pegaptanib, an anti- vascular endothelial growth factor aptamer, for
diabetic macular edema. Ophthalmology 2005;112(10):1747-1757

16.

Chun DW, Heier JS, Topping TM, Duker JS, Bankert JM. A pilot study of
multiple intravitreal injections of ranibizumab in patients with centerinvolving clinically significant diabetic macular edema. Ophthalmology
2006;113:1706-1712.

17.

Nguyen QD, Tatlipinar S, Shah SM, Haller JA, Quinlan E, Sung J.
Vascular Endothelial Growth Factor Is a Critical Stimulus for Diabetic
Macular Edema. American Journal of Ophthalmology 2006;142(6):961969.

18.

Haritoglou C, Kook D, Neubauer A, Wolf A, Priglinger S, Strauss R.
Intravitreal Bevacizumab (Avastin) Therapy For Persistent Diffuse Diabetic
Macular Edema. Retina 2006;26(9):999-1005.

19.

Arevalo JF1, Fromow-Guerra J, Quiroz-Mercado H, Sanchez JG, Wu L,
Maia M et al. Primary intravitreal bevacizumab (Avastin) for diabetic

174

macular edema: results from the Pan-American Collaborative Retina
Study Group at 6-month follow-up. Ophthalmology 2007;114(4):743-750.
20.

Diabetic Retinopathy Clinical Research Network1, Scott IU, Edwards AR,
Beck RW, Bressler NM, Chan CK, Elman MJ et al. A Phase II
Randomized Clinical Trial of Intravitreal Bevacizumab for Diabetic Macular
Edema. Ophthalmology 2007;114(10):1860-1867.

21.

Ahmadieh H, Ramezani A, Shoeibi N, Bijanzadeh B, Tabatabaei A,
Azarmina M et al. Intravitreal bevacizumab with or without triamcinolone
for refractory diabetic macular edema; a placebo-controlled, randomized
clinical trial. Graefes Arch Clin Exp Ophthalmol 2007;246(4):483-489.

22.

Kumar A, Sinha S. Intravitreal bevacizumab (Avastin) treatment of diffuse
diabetic macular edema in an Indian population. Indian J Ophthalmol
2007;55:451-455.

23.

Gragoudas ES, Adamis AP, Cunningham ET, Feinsod M, Guyer DR.
Pegaptamib for neovascular age-related macular degeneration. N Engl J
Med 2004;351:2805-2816.

24.

Rosenfeld PJ1, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY et
al. Ranibizumab for neovascular age-related macular degeneration. N
Engl J Med 2006;355(4):1419–1431

175

25.

Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY et al.
Ranibizumab versus verteporfin for neovascular age-related macular
degeneration. N Engl J Med 2006;355(14):1432-1444.

26.

Heier JS, Boyer DS, Ciulla TA, Ferrone PJ, Jumper JM, Gentile RC et al.
Ranibizumab Combined With Verteporfin Photodynamic Therapy in
Neovascular Age-Related Macular Degeneration. Arch Ophthalmol
2006;124(11):1532-1542.

27.

Mathalone N, Arodi-Golan A, Sar S, Wolfson Y, Shalem M, Lavi I et al.
Sustained elevation of intraocular pressure after intravitreal injections of
bevacizumab in eyes with neovascular age-related macular degeneration.
Graefes Arch Clin Exp Ophthalmol 2012;250(10):1435-1440.

28.

Arikan G, Saatci AO, Oner FH. Immediate intraocular pressure rise after
intravitreal injection of ranibizumab and two doses of triamcinolone
acetonide. International Journal Of Ophthalmology 2011;4 (4):402.

29.

Good T J, Kimura AE, M Ava N, Kahook MY. Sustained elevation of
intraocular pressure after intravitreal injections of anti-VEGF agents.
British Journal Of Ophthalmology 2011;95 (8):1111-1114.

30.

Tseng J, Vance S, Della Torre K, Mendonca L, Cooney M, Klancnik, J.
Sustained increased intraocular pressure related to intravitreal
antivascular endothelial growth factor therapy for neovascular age-related
macular degeneration. J Glaucoma 2012;21(4):241-247.

176

31.

Bakri S, Moshfeghi D, Francom S, Rundle A, Reshef D, Lee, P. Intraocular
Pressure in Eyes Receiving Monthly Ranibizumab in 2 Pivotal AgeRelated Macular Degeneration Clinical Trials. Ophthalmology
2014;121(5):1102-1108.

32.

Singh R, Kim J. Ocular hypertension following intravitreal anti-vascular
endothelial growth factor agents. Drugs & Aging 2012;29(12):949-956.

33.

Fujimoto JG. Optical Coherence Tomography of Ocular Diseases. 2nd ed.
Thorofare, NJ: Slack Inc;2004:714.

34.

Mwanza J-C, Oakley JD, Budenz DL, Anderson DR. Ability of Cirrus HDOCT Optic Nerve Head Parameters to Discriminate Normal from
Glaucomatous Eyes. Ophthalmology 2011;118(2).

35.

Foo L-L, Perera SA, Cheung CY, et al. Comparison of scanning laser o
phthalmoscopy and high-definition optical coherence tomography
measurements of optic disc parameters. Br J Ophthalmol 2012;96(4):576580.

36.

Meditec CZ. Stratus OCT User’s Manual. Dublin, CA: Carl Zeiss Meditec;
2003.

37.

Vizzeri G, Balasubramanian M, Bowd C, Weinreb RN, Medeiros FA,
Zangwill LM. Spectral domain-optical coherence tomography to detect
localized retinal nerve fiber layer defects in glaucomatous eyes. Opt
Express 2009;17(5):4004.

177

38.

Alencar LM, Bowd C, Weinreb RN, Zangwill LM, Sample PA, Medeiros
FA. Comparison of HRT-3 Glaucoma Probability Score and Subjective
Stereophotograph Assessment for Prediction of Progression in Glaucoma.
Invest Ophthalmol Vis Sci 2008;49(5):1898.

39.

Kummet CM, Zamba KD, Doyle CK, Johnson CA, Wall M. Refinement of
Pointwise Linear Regression Criteria for Determining Glaucoma
Progression. Invest Ophthalmol Vis Sci 2013;54(9):6234.

40.

Wessel MM, Aaker GD, Parlitsis G, Cho M, Dʼamico DJ, Kiss S. Ultra–
Wide-Field Angiography Improves The Detection And Classification Of
Diabetic Retinopathy. Retina 2012;32(4):785-791.

41.

Nicholson L, Vazquez-Alfageme C, Ramu J, et al. Validation of Concentric
Rings Method as a Topographic Measure of Retinal Nonperfusion in
Ultra-Widefield Fluorescein Angiography. Am J Ophthalmol 2015;160(6).

42.

Blodi BA, Domalpally A, Scott IU, Ip MS, Oden NL, Elledge J, et al.
Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE)
Study system for evaluation of stereoscopic color fundus photographs and
fluorescein angiograms: SCORE Study Report 9. Arch Ophthalmol
2010;128(9):1140-1145.

43.

Nguyen QD, Shah SM, Heier JS, Do DV, Lim J, Boyer D et al. Primary
End Point (Six Months) Results of the Ranibizumab for Edema of the

178

mAcula in Diabetes (READ-2) Study. Ophthalmology 2009;116(11):21752181.
44.

Nguyen QD, Shah SM, Khwaja AA, Channa R, Hatef E, Do DV et al. TwoYear Outcomes of the Ranibizumab for Edema of the mAcula in Diabetes
(READ-2) Study. Ophthalmology 2010;117(11):2146-2151.

45.

Do DV, Nguyen QD, Khwaja AA, Channa R, Sepah YJ, Sophie R et al.
Ranibizumab for Edema of the Macula in Diabetes Study. JAMA
Ophthalmol 2013;131(2):139-145.

46.

Do DV, Sepah YJ, Boyer D, Callanan D, Gallemore R, Bennett M et al.
Month-6 primary outcomes of the READ-3 study (Ranibizumab for Edema
of the mAcula in Diabetes—Protocol 3 with high dose). Eye (Lond)
2015;29(12):1538-1544.

47.

Massin P, Bandello F, Garweg JG, Hansen LL, Harding SP, Larsen M et
al. Safety and Efficacy of Ranibizumab in Diabetic Macular Edema
(RESOLVE Study): A 12-month, randomized, controlled, double-masked,
multicenter phase II study. Diabetes Care 2010;33(11):2399-2405.

48.

Mitchell P1, Bandello F, Schmidt-Erfurth U, Lang GE, Massin P,
Schlingemann RO et al. The RESTORE study: ranibizumab monotherapy
or combined with laser versus laser monotherapy for diabetic macular
edema. Ophthalmology 2011;118(4):615-625.

179

49.

Ishibashi T, Li X, Koh A, Lai TY, Lee FL, Lee WK et al. The REVEAL
Study: Ranibizumab Monotherapy or Combined with Laser versus Laser
Monotherapy in Asian Patients with Diabetic Macular Edema.
Ophthalmology 2015;122(7):1402-1415.

50.

Brown DM, Nguyen QD, Marcus DM, Boyer DS, Patel S, Feiner L et al.
Long- term Outcomes of Ranibizumab Therapy for Diabetic Macular
Edema: The 36-Month Results from Two Phase III Trials. Ophthalmology
2013;120(10):2013- 2022.

51.

Campochiaro PA, Wykoff CC, Shapiro H, Rubio RG, Ehrlich JS.
Neutralization of Vascular Endothelial Growth Factor Slows Progression of
Retinal Nonperfusion in Patients with Diabetic Macular Edema.
Ophthalmology. 2014;121(9):1783-1789.

52.

Levin A, Rusu I, Orlin A, Gupta M, Coombs P, Damico D et al. Retinal
reperfusion in diabetic retinopathy following treatment with anti-VEGF
intravitreal injections. Clin Ophthalmol 2017;11:193-200.

53.

Takis A, Alonistiotis D, Ioannou N, Kontou E, Mitsopoulou M,
Papaconstantinou D. Follow-up of the retinal nerve fiber layer thickness of
diabetic patients type 2, as a predisposing factor for glaucoma compared
to normal subjects. Clin Ophthalmol 2017;11:1135-1141.

54.

Beck M, Munk MR, Ebneter A, Wolf S, Zinkernagel MS. Retinal Ganglion
Cell Layer Change in Patients Treated With Anti–Vascular Endothelial

180

Growth Factor for Neovascular Age-related Macular Degeneration. Am J
Ophthalmol 2016;167:10-17.
55.

Saleh R, Karpe A, Zinkernagel MS, Munk MR. Inner retinal layer change
in glaucoma patients receiving anti-VEGF for neovascular age related
macular degeneration. Graefes Arch Clin Exp Ophthalmol
2017;255(4):817-824.

56.

Lim MC. Effect of Diabetic Retinopathy and Panretinal Photocoagulation
on Retinal Nerve Fiber Layer and Optic Nerve Appearance. Arch
Ophthalmol 2009;127(7):857-862.

57.

Chauhan BC, Burgoyne CF. From Clinical Examination of the Optic Disc
to Clinical Assessment of the Optic Nerve Head: A Paradigm Change. Am
J Ophthalmol 2013;156(2).

58.

Hariprasad S, Nariani A, Williams B. Long-term effect of anti-vascular
endothelial growth factor injections on intraocular pressure. Indian J
Ophthalmol 2016;64(9):643.

59.

Baek SU, Park IW, Suh W. Long-term intraocular pressure changes after
intravitreal injection of bevacizumab. Cutan Ocul Toxicol 2016;35(4):310314.

60.

Kragstrup TW, Kjaer M, Mackey AL. Structural, biochemical, cellular, and
functional changes in skeletal muscle extracellular matrix with aging.
Scand J Med Sci Sports 2011;21(6):749-757.

181

61.

Greenstein VC, Duncker T, Holopigian K, Carr RE, Greenberg JP, Tsang
SH et al. Structural And Functional Changes Associated With Normal And
Abnormal Fundus Autofluorescence In Patients With Retinitis Pigmentosa.
Retina 2012;32(2):349-357.

62.

Ismael ZF, El-Shazly AAE-F, Farweez YA, Osman MMM. Relationship
between functional and structural retinal changes in myopic eyes. Clin Exp
Optom 2017.

63.

Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ,
Wordsworth S. Ranibizumab versus Bevacizumab to Treat Neovascular
Age-related Macular Degeneration. Ophthalmology 2012;119(7):13991411.

182

Chapter 4

4

Retinal cell death following anti-VEGF treatment in a
diabetic rat model and retinal cell culture

The chapter addresses specific objectives outlined in aims 4 and 5:
4. To evaluate the effect of VEGF inhibition on neuronal cells in a STZinduced diabetic rat retina by performing intravitreal anti-VEGF injections
with different doses.
5. To determine if exposure to different doses of anti-VEGF alter retinal
cells metabolic activity and function or induce toxicity by various
colorimetric assays.
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4.1 Introduction
Diabetic retinopathy (DR) is the result of microvascular retinal changes
caused by hyperglycemia which alter the blood-retinal barrier (BRB). In DR,
hyperglycemia results in enhanced production of vascular endothelial growth
factors (VEGF), advanced glycated end products, nitric oxide, oxidative stress
and inflammation within the eye1. The factors increase the permeability of BRB,
resulting in accumulation of extracellular fluid within the retina and the
development of diabetic macular edema (DME). If the leakage is centralized
within the macula, the condition may lead to significant loss of central visual
function and acuity.
Inhibition of these unregulated factors can reduce the developing leakage,
so the gold standard treatment for DME is intravitreal anti-VEGF injections2.
Intravitreal anti-VEGF injections inhibit the action of VEGF, decreasing
permeability, leakage, and proliferation of blood vessels. While excess VEGF is
harmful, past studies have found that VEGF is involved in neuroprotection by
protecting retinal cells against the damaging insults of hypoxia, glutamate
excitotoxicity and deprivation of serum3-10.
Over the past decade, there have been increased clinical reports of
diabetic patients on anti-VEGF therapy developing signs of glaucoma and optic
neuropathy. Diabetes is already a risk factor for the development of glaucoma
and the use of anti-VEGFs might augment the risk11. In addition to this, our past
research has demonstrated that over 24 months, DME patients undergoing anti-
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VEGF therapy have decreased retinal nerve fiber layer (RNFL) thickness,
increased cup volume, increased vertical cup/disk (C/D) ratio that is dependent
on number of injections and show deterioration of peripheral vision. There is an
uncertainty in regards to whether eliminating the neuroprotective role of VEGF
through anti-VEGF therapy causes optic neuropathy and death of retinal cells.
With newer, higher affinity anti-VEGFs being introduced into the market, the
question remains whether or not neuronal cells in the diabetic retina may be
further affected by the treatment.
The purpose of the following study is to examine whether increased
exposure to anti-VEGFs will result in increased retinal cell death. First, the effects
of VEGF inhibition on neuronal cells in a streptozotocin (STZ)-induced diabetic
rat retina will be evaluated by performing intravitreal anti-VEGF injections of
different doses. Second, we will determine whether the exposure to different
doses of anti-VEGF alters retinal cells metabolic activity or induces toxicity by
various colorimetric assays.
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4.2 Methods
4.2.1

Diabetic Animal Model
Experimental protocols were approved by Animal Use Committee of

Western University. Animals were approved by Animal Care and Veterinary
Services (ACVS) of Western University and complied with the NIH Guide for the
Care and Use of Laboratory Animals (NIH publication no. 80-23, revised in
1996). Animal care adhered to the Guiding Principles in the Care and Use of
Animals.
Male Sprague-Dawley rats (250-300 grams. 7-8 weeks old) were obtained
from Charles River (Charles River Canada Ltd., Saint-Constant, Quebec,
Canada). Diabetes was induced in 25 randomly selected rats by a single
intraperitoneal injection of streptozotocin (STZ) (Sigma-Aldrich, St. Louis, MO,
65mg/kg in citrate buffer at a pH of 5.6)12. The remaining 25 rats were designated
as control and were injected with an identical volume of citrate buffer13, 14. Three
days following STZ injection, the blood glucose levels for each rat were
measured on an automated OneTouch Ultra glucometer (LifeScan Inc., Milpitas,
California, USA). A blood glucose reading of >20 mmol/L was considered
diabetic and the rat was used for further experimentation. To prevent
ketoacidosis, diabetic rats were injected with an insulin implant (2 U/d, Linshin
Canada Inc., Toronto, Ontario, Canada) that released small doses of insulin. For
the duration of 5 months, diabetic rats were routinely monitored through body
weight measurements and monitoring of blood glucose levels. The control and
diabetic groups were comprised of five animals for each experimental procedure.
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4.2.2

Drug Administration
After 5 months, rats received intravitreal injections. For each intravitreal

injection, rats were anesthetized with 4% isofluorane during the induction phase
and 3% for maintenance level. Prior to the injection, the eye was disinfected with
topical povidone iodine eye drops. A 30 gauge needle was used to administer the
intravitreal injection to the inferior temporal quadrant, posterior to the limbus. For
each rat, the right eye was the test eye and the left eye was the control, injected
with saline. With 25 control rats and 25 STZ-induced diabetic rats, each group
had a n=5 consisting of 5 rats receiving 1 unit of 0.3375 mg/mL (final
concentration in the eye being 0.0625 mg/mL, which is half the clinical dose)
injection, 5 rats receiving 1 unit 0.675 mg/mL (final concentration being 0.125
mg/mL, clinical dose) injection, and 5 rats receiving 1 unit 1.35 mg/mL (final
concentration being 0.25 mg/mL-double the clinical dose) injection of rat antiVEGF (AF564; R&D Systems, Minneapolis, MN, USA). Five rats also received 1
unit of Ranibizumab (Lucentis, 0.5 mg in 0.05 mL solution for injection; Novartis
Pharmaceuticals Canada Inc., Quebec, Canada) at 0.675 mg/mL (final
concentration being 0.125 mg/mL-clinical dose). These injections were
performed once a week for 3 weeks to simulate the injection frequency of human
patients receiving injections once a month for the duration of 3 months. The
remaining 5 rats received an injection of 1 unit 0.675 mg/mL (final concentration
being 0.125 mg/mL-clinical dose) only once to analyze the effects of frequency of
injections. The needle remained in the eye for 3-4 seconds before being drawn
out to avoid reflux. Once finished, the isoflurane was shut off and the rat was
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maintained on oxygen until fully recovered. At week 4, rats were euthanized in a
carbon dioxide gas chamber, eyes were enucleated, fixed in 4%
paraformaldehyde for 24 hours and placed in 70% ethanol for paraffin
embedding.

4.2.3

TUNEL Assay
Following paraffin-processing, the eye tissues were sectioned to a

thickness of 4 µm along the sagittal plane of the eye and transferred to positivelycharged, transparent microscope slides (VWR, Radnor, PA). The slides were
stored in -80°C until staining. To evaluate tissue integrity, efficacy of tissue
preservation and to determine optic nerve location, every tenth slide was stained
with Hematoxylin and Eosin according to standard protocol.
TUNEL Assay was performed to evaluate apoptotic cells. The sections
were dewaxed and stained using the TUNEL method according to the
manufacturer’s protocol (In Situ Cell Death Detection Kit, Fluorescein; Ref.
11684795910 Roche Applied Science, Indianapolis, Indiana, USA). In the assay,
the enzyme terminal deoxynucleotidyl transferase catalyzes the reaction that
labels the sites of DNA breaks with deoxyuridine. Slides were counterstained
with 1µM DAPI for 10 minutes at room temperature to identify nuclei and washed
with phosphate-buffered saline (PBS) before being put under cover glass.
Sections were imaged with a Zeiss LSM 510 META confocal microscope
equipped with an AxioCam MR3 (Carl Zeiss Canada, North York, Ontario,
Canada). To quantify the number of TUNEL-positive cells in the retina for the
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control and diabetic rats, cell bodies were counted in each layer by two graders.
The graders were masked to the type of animal and purpose of the study.

4.2.4

Mixed Retinal Cell Culture
Eyes from 1 week old Sprague-Dawley rats were enucleated en bloc, and

placed in CO2-independent medium supplemented with 0.1% antibioticantimycotic (Ref. 15240096 Thermo Fisher Scientific, Waltham, Massachusetts,
USA) and 4mM L-glutamine. Eyes were dissected and retinas were extracted
within 1 hour of enucleation. Retinal cells were washed with Hank's Balanced
Salt Solution supplemented with 1% penicillin, placed in a 0.2% papain activated
solution, and incubated in a 37°C water bath for 20 minutes with gentle stirring
every 5 minutes. Digestion was stopped with the addition of 0.5 μL of DNAse1
(114 U/μL) and 1mL of warm Neurobasal A medium (NBA) supplemented with
2% fetal bovine serum (FBS), 0.5 mM L-glutamine, and 2% B-27 (Ref. 17504044
Thermo Fisher Scientific, Waltham, Massachusetts, USA). Retinal cells were
dissociated by trituration in NBA and the suspension was centrifuged at 68 xg for
4 minutes. The cell pellet was resuspended in fresh NBA. The cells were seeded
at 5x105 cells per well onto 24-well plates containing 12-mm glass cover slips
precoated sequentially with poly-D-lysine (2μg/cm2 for 2 hours at 37°C) and
laminin (1μg/cm2 overnight at 37°C). Cells were maintained at 37°C in a 5% CO2
incubator.

4.2.5

Dosage
NBA was refreshed two days after plating. On the fourth day of cultivation,

the medium was removed from the mixed retinal cell cultures and replaced with
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medium containing ranibizumab (Lucentis, Novartis Pharmaceuticals Canada
Inc., Quebec, Canada) diluted down to clinical relevant concentrations (0.125
mg/mL) as well as half the clinical dose (0.0625 mg/mL) and double the clinical
dose (0.25 mg/mL). Control wells contained only medium and no anti-VEGF (0
mg/mL). In another subset of experiments, mixed retinal cell cultures were also
exposed to medium containing rat anti-VEGF (AF564; R&D Systems,
Minneapolis, MN, USA) diluted down to the same concentrations. The cells were
exposed to these concentrations for 48 or 72 hours at 37°C in a 5% CO2
incubator.

4.2.6

Immunohistochemistry
Following 48 or 72 hours of exposure to anti-VEGF, the cells were fixed

with 100% methanol for 5 minutes at -20°C for Thy 1.1 labelling. The cells were
incubated for 1 hour at room temperature with 1% bovine serum albumin (BSA),
10% normal goat serum, and 0.3M glycine in 0.1% PBS-Tween as per the
manufacturer’s protocol. This increased the permeability of the cells and blocked
non-specific protein-protein interactions. The cells were incubated for one hour at
room temperature with a mouse anti-rat primary antibody against CD90/Thy 1.1
(1:200; ab225; Abcam, Toronto, Ontario, Canada) followed by a goat anti-mouse
IgG secondary antibody conjugated to Alexa Fluor 488 (1:1000; Life
Technologies Inc., Burlington, Ontario, Canada) at room temperature in the dark
for 1 hour.
For double-labeling studies, cells were blocked in a blocking buffer
consisting of 1X PBS, 5% normal goat serum, and 0.3% Triton X-100 for 1 hour
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in room temperature as per the manufacturer’s protocol. Primary and secondary
antibodies were prepared in an antibody dilution buffer consisting of 1X PBS, 1%
BSA, and 0.3% Triton X-100. The cells were incubated overnight at 4°C with a
chicken anti-rat primary antibody Class III β-Tubulin antibody (1:400; TUJ-1;
ab107216; Abcam, Toronto, Ontario, Canada), rabbit anti-rat primary Brn3a
antibody (1:100; ab81213; Abcam, Toronto, Ontario, Canada), or rabbit anti-rat
primary cleaved caspase-3 antibody (1:400; Asp175; Cell Signaling Technology
Inc., Boston, Massachusetts, USA). After washing with PBS, cells were
incubated for one hour in the dark with goat anti-chicken IgG secondary antibody,
Texas Red (1:1000; Life Technologies Inc., Burlington, Ontario, Canada), and
goat anti-rabbit IgG secondary antibody conjugated to Alexa Fluor 488 (1:1000;
Life Technologies Inc., Burlington, Ontario, Canada). Cells were counterstained
with 1µM DAPI for 10 minutes at room temperature to identify nuclei, washed
with PBS, and mounted with Fluoromount G (Electron Microscopy Sciences,
Hatfield, PA) on positively charged slides (VWR, Radnor, PA). Antibody
concentrations were individually optimized to achieve optimal fluorescence with
minimal background staining. Images were taken using a Zeiss Axio Imager.Z1
fluorescent microscope (Carl Zeiss Canada, Toronto, ON, Canada) equipped
with an AxioCam MR3 (Carl Zeiss Canada).
Negative controls were utilized for every round of slide staining to
eliminate suspicion of non-specific secondary antigen binding. For single-staining
optimization experiments using anti-CD90/Thy 1.1, one slide was exposed to the
appropriate secondary antibody in absence of its respective primary antibody.
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For dual-staining experiments using both anti-TUJ-1 and anti-Brn3a or anticleaved caspase-3, one slide served as a control for each of the following
conditions: TUJ-1 secondary antibody alone in absence of primary, Brn3a or
cleaved caspase-3 secondary antibody alone in absence of primary, and both
TUJ-1 and Brn3a or cleaved caspase-3 secondary antibodies in the absence of
either primary antibody.

4.2.7

Colorimetric Assays
After 48 or 72 hours of treatment with the different doses of anti-VEGF,

three colorimetric assays were performed; MTT (Thiazolyl Blue Tetrazolium
Bromide) assay (M2128-1G; Sigma-Aldrich, St. Louis, Missouri, USA), lactate
dehydrogenase (LDH) assay (11644793001; Roche Life Science, Laval, Quebec,
Canada), and the cell death detection ELISA assay (11544675001; Roche Life
Science, Laval, Quebec, Canada). The colorimetric assays were performed as
per the manufacturers’ instructions. The MTT assay assessed cellular metabolic
activity of the experimental cells to the control. The LDH and cell death detection
ELISA assays were used to evaluate cytotoxicity of the experimental cells to the
control cells by examining cell death through necrosis in the LDH assay and cell
death through apoptosis in the ELISA assay. Protein concentrations (23225;
Pierce™ BCA Protein Assay Kit, Thermo Fisher Scientific, Waltham,
Massachusetts, USA) were measured for each sample to normalize the
absorption data of the LDH and cell death detection ELISA assays.

4.2.8

Statistical Analysis

Statistically analysis was performed using one-way ANOVA with a
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Bonferroni's multiple comparison test and an unpaired t-test on the GraphPad
Prism 5 software (GraphPad Software, La Jolla, CA). ANOVA with Bonferroni
method was performed as outlined in J Neter, W Wasserman, and MH Kutner,
Applied Linear Statistical Models, 3rd edition, Irwin, 1990. All data was expressed
as mean ± SD and accepted as statistically significant if p<0.05. A correction of
p<0.017 was applied for the Bonferroni's multiple comparison test.

193

4.3 Results
4.3.1

Body weight and blood glucose levels
The body weight and blood glucose levels of the control and STZ-induced

diabetic male Sprague-Dawley rats were monitored (Table 4.1). Five months post
STZ injection, diabetic rats had a significant decrease in their body weight and a
significant increase in the blood glucose levels compared to the non-diabetic
control rats. The changes indicate that diabetic dysmetabolism was established
and verifies that a diabetic rat model was used.

4.3.2

Increasing anti-VEGF concentrations caused more death in
vivo
To determine whether different doses of anti-VEGF result in increased

apoptotic cells in the retina, sagittal eye sections of control rats and STZ-induced
diabetic rats underwent TUNEL staining. Imaging under a fluorescent microscope
revealed that as the concentration of anti-VEGF increased, more apoptotic cells
were present in both the control (Figure 4.1) and STZ-induced diabetic rats
(Figure 4.2). Apoptotic cells were localized to the ganglion cell layer (GCL) and
the inner nuclear layer (INL). When quantifying the number of TUNEL-positive
cells in the retina of the control rats, untreated control (0 mg/mL) had a baseline
number of 0.64 ± 1.29 apoptotic cells. At half the clinical dose (0.0625 mg/mL),
the number increased to 1.60 ± 1.82 apoptotic cells, at the clinical dose (0.125
mg/mL) to 2.40 ± 2.07 apoptotic cells, and at double the clinical dose (0.25
mg/mL) the number significantly increased (p=0.0004) to 4.40 ± 0.89 apoptotic
cells
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Table 4.1. Body weights and serum glucose levels of control and
STZ-induced diabetic rats.

Parameter

Control

STZ-induced
diabetic rats

P-Value

Start

240.4

245.5

0.09*

Finish

481.9

417.3

0.0001*

Blood Glucose
(mmol/L)

5.8

17.8

0.0001*

Body Weight (g)

Table 6 *Unpaired t-test
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Figure 4.1. TUNEL staining of control rat retina. TUNEL staining performed in
control rats showed increased apoptotic cells in the ganglion cell layer following
different doses of anti-VEGF injections compared with untreated retina from the
control group. Blue represents DAPI-stained nuclei and green represents TUNEL
staining. Magnification x40. n=5 for each group. Scale bar: 50 µm.
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Figure 28 TUNEL staining of control rat retina
Control

Dapi
TUNEL

0.0625 mg/mL

0.25 mg/mL
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Figure 4.2. TUNEL staining of diabetic rat retina. TUNEL staining performed
in STZ-induced diabetic rats showed increased apoptotic cells in the ganglion cell
layer following different doses of anti-VEGF injections compared with untreated
retina from the diabetic control group. Blue represents DAPI-stained nuclei and
green represents TUNEL staining. Magnification x40. n=5 for each group. Scale
bar: 50 µm.
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Figure 29 TUNEL staining of diabetic rat retina
Control

Dapi
TUNEL

Lucentis-0.125 mg/mL

0.25 mg/mL
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compared to the control (Figure 4.3A). For the STZ-induced diabetic rats, control
had a baseline number of 0.46 ± 1.06 apoptotic cells. The number significantly
increased at half the clinical dose to 2.60 ± 1.34 (p=0.01), 4.5 ± 3.32 at the
clinical dose (p=0.02), and 6.8 ± 2.95 (p=0.03) at double the clinical dose (Figure
4.3B).

4.3.3

No difference in cell death between the clinical dose of
ranibizumab and rat anti-VEGF
In control rats when comparing the clinical dose of ranibizumab (Lucentis-

0.125 mg/mL) to the clinical dose of rat anti-VEGF (0.125 mg/mL) in regards to
the amount of apoptotic cells, both were not significantly different from one
another despite rat-anti-VEGF showing higher numbers of apoptotic cells (2.40 ±
2.07 cells) compared to ranibizumab (1.25 ± 0.96 cells) and untreated control
(0.64 ± 1.29 cells) (Figure 4.4A). Similarly, in the diabetic rats, ranibizumab (2.00
± 1.23) and rat anti-VEGF (4.5 ± 3.32) were also not significant to each other but
both had significantly increased (p<0.03) apoptotic cells compared to untreated
diabetic control (Figure 4.4B).

4.3.4

Frequency of injections has no effect on apoptotic cells
The frequency of injections did not have a significant effect on the number

of apoptotic cells. In the control rats, single versus triple injections of the clinical
dose of rat-anti-VEGF showed no significant difference (p=0.79). Single
injections resulted in 2.00 ± 2.16 apoptotic cells while 3 injections resulted in 2.4
± 2.074 apoptotic cells. Control rats injected with anti-VEGF had no significant
difference (p>0.36) when compared to untreated control (0.64 ± 1.29 cells)
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Figure 4.3. Apoptotic death rates following different doses of rat anti-VEGF
in control and diabetic rats. The number of TUNEL-positive cells in the GCL
was significantly greater at double the clinical dose (0.25 mg/mL) in the control
rats (A) and significantly greater at half the clinical (0.0625 mg/mL), clinical
(0.125 mg/mL), and double the clinical dose (0.25 mg/mL) in the diabetic rats (B)
compared to untreated controls. Data are expressed as means ± SD. n=5 for
each group. *p < 0.03, ***p=0.0004 compared with controls.
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Figure 30 apoptotic death following different doses of rat
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Figure 4.4. Apoptotic cell death rates between the clinical dose of rat antiVEGF and ranibizumab in control and diabetic rats. Comparing the clinical
dose of ranibizumab (Lucentis-0.125 mg/mL) to the clinical dose of rat anti-VEGF
(0.125 mg/mL) in control (A) and diabetic (B) rats, neither was significant to each
other regarding the number of TUNEL-positive cells. Compared to the untreated
control in the control rats (A), the number of TUNEL-positive cells was not
significantly greater at the clinical dose of ranibizumab and rat anti-VEGF but in
the diabetic rats (B), both the clinical dose of ranibizumab and rat anti-VEGF had
significantly increased numbers of TUNEL-positive cells compared to untreated
diabetic control. Data are expressed as means ± SD. n=5 for each group. *p <
0.03, compared with controls.
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Figure 31 No significant difference in the number of apoptotic cell death
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Figure 4.5. Effects of frequency of injections on the number of TUNELpositive cells in control and diabetic rats. Injecting the clinical dose of rat-antiVEGF once versus three times showed no significant difference between each
other for both the control (A) and diabetic (B) rats. Injecting once versus three
times in the control rats (A) had no significant difference when compared to
untreated control. In the diabetic rats (B), injecting once or 3 times both showed
significantly increased TUNEL-positive cells compared to untreated diabetic
controls. Data are expressed as means ± SD. n=5 for each group. *p < 0.03,
compared with controls.

205

Figure 32 Frequency of injections had no significant effect on
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(Figure 4.5A). In the diabetic rats, a single injection of the clinical dose (3.40 ±
1.95 cells) had no significant differences from a dose consisting of 3 injections
despite having more apoptotic cells (4.50 ± 3.32 cells). A single dose injection as
compared to 3 injections both had significantly increased (p<0.03) number of
apoptotic cells relative to untreated diabetic control (Figure 4.5B).

4.3.5

Verification of mixed retinal cell culture
The mixed retinal cell cultures were stained for Class III β-Tubulin, a

known neuronal marker, with BRN3A and Thy 1.1 which are both retinal ganglion
cell (RGC)-enriched markers. Cells were imaged at 60x magnification. Alexa
Fluor 488 green emissions corresponded with staining for Class III β-Tubulin,
suggesting that retinal neuronal cells were present in the mixed retinal cell
culture. The expression of Brn3a and Thy 1.1 was indicative of the mixed retinal
cell culture containing RGC’s. Initial immunofluorescence of primary rat retinal
cell cultures showed positive expression of Brn3a, Class III β-Tubulin (Figure
4.6A) and Thy1.1 (Figure 4.6B). Confocal triple immunofluorescence indicated
the co-staining of Thy1.1 (Figure 4.6D), Class III β-Tubulin (Figure 4.6E), and
nuclear DAPI (Figure 4.6F) in cells at day 3 of culture (merged image in Figure
4.6C). The RGCs in culture showed dendritic outgrowth and elongation with
axonal processes frequently contacting each other.

4.3.6

Increasing anti-VEGF concentrations caused cell death in
vitro
Examining RGC’s under different concentrations of ranibizumab using

immunocytochemistry, as the anti-VEGF concentration increased, the
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Figure 4.6. Expression of retinal ganglion cell (RGC)-specific markers in the
primary rat retinal cell culture. A-B: Immunofluorescence of primary rat retinal
cell culture at day 1 of culture showed positive expression of Brn3a, Class III βTubulin (A) and Thy1.1 (B). Confocal triple immunofluorescence showed the costaining of Thy1.1 (D), Class III β-Tubulin (E), and nuclear DAPI (F) in cells at
day 3 of culture (merged image in C). The RGCs in culture showed dendritic
outgrowth and elongation with axonal processes frequently contacting each
other. A-B Magnification x80. C-F Magnification x60. Scale bars: 20 µm.
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Figure 33 Expression of retinal ganglion cell
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morphology of the RGC’s changed as well (Figures 4.7 and 4.8). Visually, as the
anti-VEGF concentration increased, the number of RGC’s decreased, fewer
contacts between RGC’s were observed and fewer dendritic and axonal
outgrowths were detected. The observations were conducted at both 48 (Figure
4.7) and 72 (Figure 4.8) hours.
Immunostaining of cleaved caspase-3 in the mixed retinal cell culture
under different ranibizumab concentrations showed increased apoptotic cell
death in half the clinical (0.0625 mg/mL), clinical (0.125 mg/mL), and double
(0.25 mg/mL) the clinical doses compared to untreated control (0 mg/mL). The
observations were made at both 48 (Fig 4.9) and 72 (Fig 4.10) hours.
Double-labeling studies of Class III β-Tubulin and cleaved caspase-3
indicated that at double the clinical dose (0.25 mg/mL) RGC’s began to die from
apoptosis. At half the clinical (0.0625 mg/mL), clinical (0.125 mg/mL), and double
(0.25 mg/ml) the clinical doses, the surrounding supporting cells were dying
through apoptosis in the mixed retinal cell culture (Figure 4.11). This was also
observed in the TUNEL analysis of retinal sections, since death was observed in
the INL as well for both the control and diabetic rats (Figure 4.12).

4.3.7

Increased ranibizumab concentrations result in
decreased cellular metabolic activity
At 48 hours, as ranibizumab concentrations increased, cellular metabolic

activity decreased as measured using the MTT assay. Cellular metabolic activity
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Figure 4.7. Morphological effect of different concentrations of ranibizumab
on RGCs following 48 hours post treatment. RGCs were stained for nuclei
(blue) and Class III β-tubulin (red). Immunofluorescence of RGCs under different
concentrations of ranibizumab for 48 hours showed that as the concentration
increased, the morphology of the RGC’s changed. As the concentration went
from untreated control to double the clinical dose (0.25 mg/mL), the number of
RGC’s decreased, had fewer contacts between each other, and had fewer
dendritic outgrowths. Magnification x60. Scale bar: 20 µm.

211

Figure 34 of different concentrations
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Figure 4.8. Morphological effect of different concentrations of ranibizumab
on RGCs following 72 hours post treatment. RGCs were stained for nuclei
(blue) and Class III β-tubulin (red). Immunofluorescence of RGCs under different
concentrations of ranibizumab for 72 hours showed that as the concentration
increased, the morphology of the RGC’s continued to change. As the
concentration went from untreated control to double the clinical dose (0.25
mg/mL), the amount of RGC’s showed a further decrease in number, had fewer
contacts between each other and had fewer dendritic outgrowths. Magnification
x60. Scale bar: 20 µm.
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Figure 35 of different concentrations of
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Figure 4.9. Apoptotic cell death upon exposure to different concentrations
of ranibizumab following 48 hours post treatment. Immunofluorescence
staining for cleaved caspase-3 (green) and nuclei (blue) in the mixed retinal cell
culture under different ranibizumab concentrations for 48 hours showed that
there was an increase in apoptotic cell death in half the clinical (0.0625 mg/mL),
clinical (0.125 mg/mL) and double (0.25 mg/mL) the clinical doses compared to
untreated control (0 mg/mL). Magnification x20. Scale bar: 50 µm.
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Figure 36 upon exposure to different concentrations
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Cleaved caspase-3
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Figure 4.10. Apoptotic cell death upon exposure to different concentrations
of ranibizumab following 72 hours post treatment. Immunofluorescence
staining for cleaved caspase-3 (green) and nuclei (blue) in the mixed retinal cell
culture under different ranibizumab concentrations for 72 hours corresponded
with the 48 hour results. There was increased apoptotic cell death observed at
half the clinical (0.0625 mg/mL), clinical (0.125 mg/mL), and double (0.25 mg/mL)
the clinical doses compared to untreated control (0 mg/mL). Magnification x20.
Scale bar: 50 µm.
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Figure 37 upon exposure to different
Control

Dapi
Cleaved caspase-3
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Figure 4.11. Apoptotic cell death of support cells surrounding RGCs.
Performing double-labeling studies of class III β-Tubulin (red) and cleaved
caspase-3 (green) indicated that RGCs began to die from apoptosis at double
the clinical dose (0.25 mg/mL) (arrowhead). At all doses, it was the surrounding
supporting cells around the RGCs that were dying off through apoptosis. Images
are shown with DAPI staining the nuclei in blue. Magnification x60. Scale bar: 20
µm.
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Figure 38 with class III β-Tubulin and cleaved
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Figure 4.12. Apoptosis in the INL following TUNEL staining. TUNEL analysis
of retinal sections showed apoptosis in the INL (arrowhead) as well for both the
control (A) and diabetic (B) rats. Blue represents DAPI-stained nuclei and green
represents TUNEL staining. INL, inner nuclear layer. Magnification x40. Scale
bar: 50 µm.
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Figure 39 VEGF inhibition resulted in the apoptosis
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decreased at half the clinical dose by 2.37% (0.0625mg/mL; 69.87 ± 8.20 %,
p=0.14), significantly decreased at the clinical (0.125 mg/mL; 68.18 ± 6.00%,
p=0.003) and double the clinical doses (69.74 ± 4.50%, p=0.04) by 4.06% and
2.5% respectively compared to untreated control (0 mg/mL; 72.24 ± 7.18 %)
(Figure 4.13A). At 72 hours, the cellular metabolic activity further decreased and
displayed the same trend as cells at 48 hours. Compared to the untreated control
(67.15 ± 3.34), the cellular metabolic activity decreased at half the clinical dose
by 0.56% (0.0625mg/mL; 66.59 ± 4.07 %, p=0.57), and significantly decreased at
the clinical (0.125 mg/mL; 63.51 ± 4.70%, p=0.002) and double the clinical dose
(62.52 ± 5.04%, p<0.0001) by 3.64% and 4.63% respectively (Figure 4.13B).

4.3.8

Increasing ranibizumab concentrations result in
increased necrosis
Cells were treated for 48 hours with different concentrations of

ranibizumab and necrosis was measured using a LDH assay. Necrosis increased
by 14% at half the clinical dose (0.0625 mg/mL; 114.40 ± 43.48 %, p=0.33),
significantly increased by 30.2% at the clinical dose (0.125mg/mL; 130.60 ±
44.31%, p=0.04) and by 32.5% at double the clinical dose (0.25 mg/mL; 132.90 ±
29.44%, p=0.005) compared to untreated control (0 mg/mL; 100.4 ± 21.27)
(Figure 4.14A). During 72 hours, there was less necrosis compared to 48 hours
but the same trend was observed. At 72 hours, necrosis increased by 10.6% at
half the clinical dose (0.0625mg/mL; 109.00 ± 22.62%, p=0.19), significantly
increased by 27.7% at the clinical dose (0.125 mg/mL; 126.10 ± 22.57%,
p=0.002) and 22.1% at double the clinical dose (0.25 mg/mL; 120.5 ± 28.35,
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Figure 4.13. Cellular metabolic activity following different concentrations of
ranibizumab. Cellular metabolic activity, as measured using the MTT assay, was
significantly decreased at the clinical dose (0.125 mg/mL) and double the clinical
dose (0.25 mg/mL) of ranibizumab for both 48 (A) and 72 (B) hours. The cellular
metabolic activity was further decreased at 72 hours. Data is expressed as
means ± SD. n=4. *p < 0.04, **p<0.003, ***p<0.0001 compared with controls.
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Figure 40 Decreased cellular metabolic activity following
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Figure 4.14. Necrosis following different concentrations of ranibizumab.
Necrosis, as measured using the LDH assay, was significantly increased at the
clinical dose (0.125 mg/mL) and double the clinical dose (0.25 mg/mL) of
ranibizumab for both 48 (A) and 72 (B) hours. There was less necrosis activity
present at 72 hours compared to 48 hours. Data is expressed as means ± SD.
n=4. *p < 0.04, **p<0.005 compared to the controls.

226

Figure 41 Increased necrosis following different concentrations
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p=0.03) when compared to the untreated control (98.40 ± 15.25%) (Figure
4.14B).

4.3.9

Increased apoptosis with increasing ranibizumab
concentrations
Cells were treated for 48 hours with different concentrations of

ranibizumab, and apoptosis was measured using the cell death detection ELISA
assay. Apoptosis significantly increased at half the clinical dose (0.0625 mg/mL;
131.9 ± 43.94%, p=0.02), the clinical dose (0.125 mg/mL; 124.00 ± 22.79%,
p=0.005), and double the clinical dose (0.25 mg/mL; 137.20 ± 61.77%, p=0.04)
by 35.4%, 27.5%, 40.7% respectively when compared to untreated controls
(96.50 ± 19.34%) (Figure 4.15A). Cells displayed increased apoptosis when
treated for 72 hours and showed the same trends as in 48 hours. There was a
significant increase in apoptotic cells at half the clinical dose (0.0625 mg/mL;
142.3 ± 55.20%, p=0.01), the clinical dose (0.125 mg/mL; 137.9 ± 31.51%,
p=0.001), and double the clinical dose (0.25 mg/mL; 142.70 ± 39.79%, p=0.002)
by 47.7%, 43.3%, 48.1% respectively when compared to untreated controls
(94.60 ± 24.72%) (Figure 4.15B).

4.3.10

Increased apoptosis and necrosis with rat anti-VEGF
concentrations

Different concentrations of rat-anti-VEGF at 48 hours had a significant
increase in necrosis at half the clinical dose (0.0625 mg/mL; 134.8 ± 30.61%,
p=0.01), the clinical dose (0.125 mg/mL; 143.00 ± 33.29%, p=0.003), and double
the clinical dose (0.25 mg/mL; 172.50 ± 48.52%, p=0.0002) by 29.8%, 38%,

228

67.5% respectively when compared to untreated controls (105.00 ± 21.46%)
(Figure 4.16A). The cell death detection ELISA assay after 48 hours for different
rat anti-VEGF concentrations showed increased apoptosis at half the clinical
dose (0.0625 mg/mL; 139.80 ± 29.90%, p=0.001), the clinical dose (0.125
mg/mL; 143.10 ± 33.29%, p=0.002), and double the clinical dose (0.25 mg/mL;
152.40 ± 33.46%, p=0.0002) by 41.9%, 45.2%, 54.5% respectively when
compared to untreated controls (97.88 ± 25.41%) (Figure 4.16B).
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Figure 4.15. Apoptosis following treatments with different concentrations
of ranibizumab. Apoptosis, as measured using the cell death detection ELISA
assay, was significantly increased at half the clinical (0.0625 mg/mL), clinical
(0.125 mg/mL), and double the clinical dose (0.25 mg/mL) of ranibizumab for
both 48 (A) and 72 (B) hours. There was increased apoptosis present at 72
hours compared to 48 hours. Data is expressed as means ± SD. n=4. *p < 0.04,
**p<0.005 compared to the controls.
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Figure 42 Increased apoptosis following different concentrations
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Figure 4.16. Necrosis and apoptosis following treatments with different
concentrations of rat anti-VEGF. Necrosis (A) and apoptosis (B) at 48 hours
was significantly increased at half the clinical (0.0625 mg/mL), clinical (0.125
mg/mL), and double the clinical dose (0.25 mg/mL) of rat anti-VEGF measured
using the LDH assay and cell death detection ELISA assay respectively. Data is
expressed as means ± SD. n=4. *p < 0.01, **p<0.003, p<0.0002 compared to the
controls.
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Figure 43 Increased necrosis and apoptosis following

A

B
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4.4 Discussion
The aim of this study was to obtain in vitro and animal model mechanistic
data to correlate with in vivo clinical observations. The first consideration was
determination of the appropriate anti-VEGF concentrations. The values from the
calculations of ranibizumab dilutions in the human vitreous were correlated to the
rat vitreous, and based on the concentrations used in past studies, 0.125 mg/mL
was used as the clinical dose15, 16. The clinical intravitreal dose of ranibizumab is
0.5 mg, resulting in a concentration of 0.125 mg/ml in the vitreum of human
patients. As such, 0.125 mg/ml was the final vitreous and medium concentration
used for the in vitro and in vivo experiments16, 17. Using 0.125 mg/mL as the final
clinical concentration, half the clinical dose (0.0625 mg/mL) was also tested, as
well as double the clinical dose (0.25 mg/mL) which is also the clinically relevant
concentration of bevacizumab, another anti-VEGF clinically used for DME.
In relation to the frequency of injections, patients typically receive an antiVEGF injection once a month for 3 months and are clinically assessed on month
4. They are then treated on an as needed basis until they are clinically stable
according to their OCT tests and clinical assessments18. To simulate the
treatment regime with rats, the rodents were injected once a week for 3 weeks
and sacrificed on week 4.
Compared to normal controls, the diabetic rats were more sensitive to
different concentrations of anti-VEGF injections. Compared to untreated diabetic
controls, diabetic rats showed increased apoptotic deaths at half the clinical,
clinical, and double the clinical doses whereas, non-diabetic control rats showed
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increased apoptotic death at only double the clinical dose. The results were
expected given the nature of the disease since diabetics are more sensitive to
ocular changes compared to non-diabetics. The apoptotic death centered around
the GCL and INL which correlates with a previous study19. While anti-VEGF
therapy improves vascular changes, past studies have also indicated that VEGF
is involved in neuroprotection by protecting retinal cells against damaging insults
like hypoxia, glutamate excitotoxicity and deprivation of serum3-10, 19. To ensure
survival, retinal neurons have been shown to provide continuous trophic support.
Under ischemic conditions in the retina, VEGF expression in neurons is
increased19, 20, 21. By eliminating VEGF through intravitreal anti-VEGF injections,
neuronal cells that rely on VEGF for survival, such as bipolar, amacrine and glial
cells, are put at risk of dying19.
When comparing the clinical dose of ranibizumab and the clinical dose of
rat anti-VEGF, although there was no significant difference between the two, rat
anti-VEGF showed an increased number of apoptotic cells when compared to
ranibizumab. The non-diabetic rats were not significantly different from the
untreated control. For the diabetic rats, both clinical ranibizumab and rat antiVEGF had increased number of apoptotic cells compared to the untreated
diabetic control. The results were unexpected since ranibizumab is humanized
and species-specific. None the less, ranibizumab may have some cross over
effect in blocking rat VEGF and causing apoptotic cell death.
In regards to the frequency of injections and number of apoptotic cells,
non-diabetic and diabetic rats who received a single injection versus three
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injections showed no significant difference. Despite showing no significance, rats
that were injected three times showed higher numbers of apoptotic deaths. For
the non-diabetic rats, the results from single injections versus three injections
were not significantly different compared to the untreated control. For the diabetic
rats, having an injection, either once or three times, resulted in increased
apoptotic death compared to untreated diabetic control. Multiple injections lead to
increased apoptotic cell death due to greater reduction of VEGF and less
neuroprotection in the eye.
Most of the apoptotic death observed in vivo animal experiments occurred
in the ganglion cell layer. As such, for the in vitro experiments it was important for
the mixed retinal cell culture to contain RGCs. To test for the presence of RGCs,
cells were stained for Class III β-tubulin (TUJ-1) which is a constituent of
neuronal microtubules and frequently expressed on RGCs, as well as Brn3a and
Thy 1 which are also RGC-specific markers22. Thy1 is a glycophosphatidylinositol
anchored cell surface protein of the immunoglobulin superfamily which has been
shown to be specifically expressed on RGCs23, 24, 25. The expression of Thy 1 in
the mixed retinal cell culture was at a level similar to past studies23, 26, 27. Brn3a is
a class IV POU domain transcription factor that has an important role in
differentiation, survival, and axonal elongation during the development of
RGCs28. Brn3a has been determined to be a reliable marker of RGCs in past
studies23, 24, 29, 30. The mixed retinal cell culture used for the study had expression
of all 3 markers as well as had signs of outgrowth and elongation, indicating the
presence of RGCs.
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Exposure to increasing concentrations of ranibizumab for 48 and 72 hours
lead to a decrease in RGC’s as detected by TUJ-1 staining. In regards to
morphology, fewer contacts between RGCs and fewer outgrowths were
observed. Staining for cleaved caspase-3 revealed that half the clinical, clinical,
and double the clinical dose of ranibizumab resulted in increased apoptotic death
compared to untreated control. Co-staining with TUJ-1 showed that RGCs
remained relatively healthy and, in fact, the support cells around RGCs were the
ones dying off. The observation correlates with the animal results since apoptotic
death was also observed in the INL. No detrimental effects to RGCs as the result
of ranibizumab treatments have been detected until administering double the
clinical dose. Ranibizumab affects the supporting cells surrounding RGCs which
in turn affect the morphology of RGCs as has been previously observed in the
study. The damage to the supporting cells may affect the morphology of the optic
nerve by causing a decrease in the ganglion cell layer and an increase in the
cup/disk ratio as shown in our previous clinical study. The results correlate with
past studies that have shown that treatments with anti-VEGF decrease the
number of cells in INL but have no effect on the number of cells in GCL.19 Tests
of anti-VEGF concentrations on pure RGC cell lines have also shown no
significant changes31. Previous studies have noted that anti-VEGF alone is not
cytotoxic to RGCs but when the cells are exposed to oxidative stress, the
protective effect of VEGF is eliminated32, 33, 34. Through the use of a mixed retinal
cell culture, which is the closet cell based in vitro model to the composition of an
in vivo retina, we have verified that RGC’s are not being directly affected by
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different anti-VEGF concentrations. The anti-VEGF treatments eliminate VEGFs
neuroprotective functions, and potentially other unknown roles, causing the
surrounding supporting cells to become cytotoxic and die thereby affecting RGC
morphology.
The immunofluorescence results were supported by colorimetric assays,
which suggest that as the concentration of ranibizumab increased, a significant
decrease in cellular metabolic activity and an increase in cytotoxicity through
necrosis and apoptosis at both 48 and 72 hours occurred. In accordance with the
cleaved caspase-3 results, both half the clinical, clinical and double the clinical
dose all showed significant increase in apoptotic death when tested using the cell
death detection ELISA. Rat anti-VEGF was tested using the established
concentrations to determine whether the antibody or the anti-VEGFs vehicle
increased cell death. According to results, the antibody alone was more
cytotoxic. Results from the LDH assay demonstrated that even at half the clinical
dose, as well as at clinical and double the clinical doses, increased necrosis
occurred. The cell death detection ELISA showed further apoptotic death under
all 3 concentrations.
This is the first study to utilize a mixed retinal cell culture and conduct in
vitro and in vivo experiments that mimic clinical conditions. The benchtop
approach was a complementary addition to the overall study aimed at
determining potential mechanisms to explain the clinical observation that
repeated anti-VEGF injections may be detrimental to the optic nerve by
decreasing RNFL thickness, increasing cup volume and increasing vertical
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cup/disk ratio over time. For the aforementioned reason, the current study sought
to obtain comprehensive results by the conduct of animal and mixed retinal cell
culture experiments to determine whether different doses of anti-VEGF result in
any changes to the retina.
In conclusion, repeated anti-VEGF injections may be detrimental to the
retina by decreasing cellular metabolic activity and increasing cytotoxicity of
retinal cells through necrosis and apoptosis. The cytotoxicity of the support cells
affects RGC morphology which may explain why clinically anti-VEGF treatment
results in decreased RNFL thickness, increased cup volume and increased
cup/disk ratio. In contrast to current recommendations, the results provide a
cautionary note to monitor both the retina and optic nerve status in patients
undergoing frequent anti-VEGF injections.
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Chapter 5

5

General Discussion, Limitations, and Future Direction
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5.1 Summary of Discussion
DR is the most common microvascular complication of diabetes and the
leading cause of blindness among adults1, 2. The goal of this thesis was to
examine two common clinically-relevant treatments for DR and to determine
whether they have an iatrogenic effect on the retina and the optic nerve.
Numerous studies have been published on argon, and to a lesser extent
PASCAL, panretinal photocoagulation (PRP) for PDR and the use of anti-VEGFs
for DME. However, none of the studies have examined the effects of anti-VEGF
treatments on the optic nerve and peripheral vision. This is especially alarming
considering that over the past decade, with newer lasers being introduced into
the market and higher affinity anti-VEGFs being developed, there have been an
increasing number of reports indicating that diabetic patient’s post-PRP or
receiving anti-VEGFs developing signs of optic neuropathy and glaucoma.
In order to analyze the effects of PRP laser on the retina and optic nerve,
the primary objective was to use clinical structural (OCT, HRT) and functional
(visual field, visual acuity) diagnostic tests to monitor the retina and optic nerve.
Secondly, the intent was to observe whether PRP was beneficial and improved
diabetic ischemia. The results suggest that overall, PRP did not cause any
significant changes to the macula or RNFL thickness over a 24-month time
period. There was a slight thickening of the macula and RNFL at 6 months but
this finding was likely due to intraretinal inflammation from the treatment3, 4, 5. By
24 months, the thickness returned to baseline levels. Using the structural OCT
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and HRT diagnostic tests to analyze the optic nerve revealed that overall, the
morphology of the optic nerve appeared unchanged. There was a significant
improvement in peripheral perfusion at 12 and 24 months post laser, thus
improving the degree of ischemia in these diabetic patients. Despite the
improvement, there was no change in central vision and a progressive significant
decline in peripheral vision at 12 and 24 months post-laser was observed. The
likely cause of peripheral deterioration was the destruction of peripheral retinal
tissue by photocoagulation6, 7, 8. When glaucoma specialists who were masked to
the study were asked to grade the optic nerve photos of patients that received
PRP laser, grading of the optic nerve was much more unreliable following PRP
when compared to control eyes. Grader 1 indicated that there was a significant
increase in the cup/disk ratio at 6 and 12 months followed by a further increase at
24 months. Grader 2 indicated that there was a non-significant increase that was
happening to the optic nerve. Despite no observed morphological changes to the
optic nerve, as determined by the OCT and HRT, the optic nerve became more
difficult to grade due to non-morphological colouration changes that affected the
optic nerve post-PRP.
The following is a pilot study that assesses the effects of PRP on the optic
nerve. The results from the study highlight the importance of laser treatments in
improving the overall diabetes by increasing perfusion of blood vessels and
improving diabetic ischemia. This is the first study to correlate unreliable grading
of the optic nerve and progressive visual field loss in patients post-PRP. The
findings may explain why some diabetic patient’s post-PRP laser treatments are

248

misdiagnosed with having normal-tension glaucoma. The misdiagnosed patients
are treated with preventative glaucoma topical medications, have a number of
health related quality of life issues related to side effects and cost. The study
highlights the need for a more objective optic nerve analysis to assist clinicians in
diagnosing normal tension glaucoma in diabetic patients who have received prior
PRP.
In order to assess the effects of anti-VEGF therapy, the first objective was
to recruit treatment naïve DR patients with underlying DME in order to analyze
the effects of anti-VEGF injections and the frequency of injections on the retina
and optic nerve using in vivo clinical pathological analysis. The second objective
was to utilize an animal model to determine whether anti-VEGF therapy has any
effects on the retina and neuronal cells of STZ-induced diabetic rats. The third
objective was to generate a mixed retinal cell culture to examine whether
different doses of anti-VEGF alter retinal cell metabolic activity or induce toxicity
through the use of various colorimetric assays and immunofluorescence.
The macular thickness in anti-VEGF treated patients significantly
decreased and central vision significantly improved from baseline over a 24month time period. The results were expected as previous clinical trials and
studies suggested likewise9-16. The anti-VEGF therapy was also beneficial in
significantly improving perfusion of the diabetic eye, likely through the
stabilization of blood vessels. Analysis of the optic nerve indicated that antiVEGF therapy may be detrimental to the optic nerve by significantly decreasing
RNFL thickness, increasing cup volume and increasing vertical cup/disk ratio as
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measured on the OCT over a 24-month time period. As a secondary measure, to
eliminate the possibility of the findings being due to scanning error or the
repeatability or reproducibility of OCT, glaucoma specialists, who were masked
to the study, were asked to grade the optic nerve photos of patients that
underwent anti-VEGF therapy. Verifying the OCT data, both graders indicated a
significant increase in the vertical cup/disk ratio of patients receiving anti-VEGF
injections, whereas control patients showed no change. Data from monitoring
IOP of the patients over a 24 month period showed consistent pressure values
with no significant increase. In combination with OCT, the data suggested that
morphological changes occured to the optic nerve in DME patients undergoing
anti-VEGF therapy for which glaucoma is not the primary cause. Of note are the
differences in the OCT data of patients with diffent number of anti-VEGF
injections. Patients that received less than 10 injections had no significant
change in the cup/disk ratio whereas, patients that had more than 10 injections
had a significant increase in the cup/disk ratio. Despite the findings that the
patients that had more than 10 injections had a greater baseline vertical cup/disk
ratio than patients that had less than 10 injections, baseline vertical cup/disk ratio
between the two groups was not significantly different. In accordance, when
analyzing peripheral visual fields, although a decline in the peripheral visual fields
was observed from 6 to 24 months, it was not significant.
The overall results from using an in vivo animal model to explain retinal
changes during anti-VEGF therapy revealed that diabetic rats are much more
sensitive to anti-VEGF than non-diabetic rats. Diabetic rats had a significant
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increase in apoptotic cell deaths at half the clinical, clinical, and double the
clinical doses. In comparison, non-diabetic rats only showed significant apoptotic
cell death for double the clinical dose when compared to untreated controls.
Apoptotic death was centered around GCL and INL in both the non-diabetic and
diabetic rats, corresponding with previously published results17. VEGF has been
shown to play a neuroprotective role for retinal neurons, bipolar, amacrine and
glial cells, protecting against damaging insults like hypoxia, glutamate
excitotoxicity and deprivation of serum17-25. Eliminating VEGF through intravitreal
anti-VEGF injections increases the risk of cell death. Comparing the effects of
ranibizumab to rat anti-VEGF, rat anti-VEGF resulted in more apoptotic death but
the difference was not significant. Compared to untreated controls, no
significance in the number of apoptotic cells for the controls rats was detected.
However, both ranibizumab and rat-VEGF had significantly increased apoptotic
cells compared to untreated diabetic control rats. Though ranibizumab is
humanized and species-specific, it still appears to have some cross over effect
by blocking rat VEGF and causing apoptotic death. In regards to the frequency of
injections, a single injection resulted in less apoptotic death as compared to
having three injections of clinical doses though the difference was not significant.
Increased frequency of injections presumably resulted in increased apoptotic cell
death due to greater reduction of VEGF and less neuroprotection in the eye. In
the control rats, one or three injections resulted in no significant difference in the
amount of apoptotic cells compared to untreated controls. For the diabetic rats,
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having one injection or three injections resulted in a significant higher amount of
apoptotic death compared to untreated diabetic control.
A mixed retinal cell culture was developed for the study and verified for the
presence of RGC by the immunofluorescence of TUJ-1, Brn3a and Thy 1, all of
which are RGC-specific markers. When cells were dosed with half the clinical,
clinical, and double the clinical doses of ranibizumab, as the concentration
increased, RGC’s decreased in number, had fewer contacts between cells and
fewer outgrowths were observed. When stained with cleaved caspase-3, the
number of apoptotic deaths increased at half the clinical, clinical, and double the
clinical doses. The co-staining of caspase-3 and RGC’s revealed that
ranibizumab was likely not detrimental to RGCs unless at double the clinical
dose. For all doses, supporting cells around RGCs were dying through apoptosis,
thus affecting the morphology of the RGCs as previously described. It is likely
that anti-VEGFs eliminate VEGFs neuroprotective function, and potentially other
unknown roles, causing the surrounding supporting cells to become cytotoxic and
die thereby affecting RGC morphology. The results correlate with animal findings
since apoptotic death was also observed in INL. The finding is consistent with
clinically observed results. The dying of support cells affects RGC morphology,
which in turn could affect the morphology of the optic nerve by causing a
decrease in the ganglion cell layer and an increase in the cup/disk ratio as shown
previously. Since structural changes happen prior to functional changes, the
changes affecting the optic nerve could explain a decline in peripheral vision in
DME patients undergoing anti-VEGF therapy at 6 months.
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The results of the immunofluorescence were further supported by the
colorimetric assays which indicated that, as the concentration of ranibizumab
increased, there was a significant decrease in cellular metabolic activity and an
increase in cytotoxicity through necrosis and apoptosis at both 48 and 72 hours.
The cell death detection ELISA, in accordance with the caspase-3 results,
showed a significant increase in apoptotic cell death at half the clinical, clinical,
and double the clinical doses. Rat anti-VEGF was also tested under the same
concentrations as ranibizumab to determine whether the antibody or the antiVEGFs vehicle was causing increased cell death in retina. Findings have
established that the rat anti-VEGF was more cytotoxic than ranibizumab.
Through the LDH assay, it was observed that even half the clinical dose caused
increased necrosis as well as the clinical and double the clinical doses. The cell
death detection ELISA showed further apoptotic death with all 3 concentrations.
This is the first long-term study analyzing the effects of anti-VEGF therapy
on the optic nerve. The valuable conclusion from my study is that anti-VEGF
treatments are detrimental to the optic nerve despite improvements in central
vision based on in-vivo clinical and in-vitro studies. The finding is especially
alarming since anti-VEGFs are becoming more commonly used as the first line of
treatment due to the ease, simplicity and speed of the treatment. Recent studies
suggest eliminating the use of panretinal photocoagulation in favour of antiVEGFs for proliferative diabetic retinopathy treatments26, 27. In western Canada,
instead of administering anti-VEGFs once a month for 3 months, clinicians are
treating patients with anti-VEGF injections on the weekly basis. Currently, there
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are novel anti-VEGFs in development, such as Aflibercept (Eylea®), which are
VEGF traps and have a much higher binding affinity for VEGF, as well as longer
duration of action as compared to ranibizumab (Lucentis). Despite short-term
improvements, the possibility of long-term damage to the optic nerve and
creating another form of blindness is especially important to address and provide
a cautionary note to monitor both the retina and optic nerve status in patients
undergoing frequent anti-VEGF injections.
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5.2 Limitations
A limitation of chapter 2 when examining the effects of the PRP laser is
the low number of participants in the study. Despite meeting power number
calculations for the treatment group, at least 16 control patients in the study
would have been preferred. Although the number of participants for the control
group did not meet the limit, the control group did not show any significant
difference in any of the testing and showed stable trends.
A limitation for chapter 3 is the limited 24 month time period for the clinical
analysis of the patients. A longer duration of the study would have been preferred
to observe continued changes to the retina. Despite changes to the RNFL
thickness, increase in cup/disk ratio and slight deterioration of peripheral vision, it
is still uncertain whether or not the changes are progressive and will continue to
get worse or reach steady state over time.
The main limitation for chapter 4 is the use of rat animal models as
surrogates for humans. A rat model was used for the in vivo work and in vitro
work by generating a rat mixed retinal cell culture. Even though rodents and
humans share a large percentage of DNA, there are major differences. In
regards to diabetes, humans develop T1DM and T2DM. T1DM is associated with
absolute insulin deficiency due to autoimmune destruction of pancreatic beta
cells whereas T2DM is caused by a combination of insulin resistance and insulin
deficiency28, 29. The rats were made diabetic by pharmacological induction which
targeted and destroyed the beta-cells. Furthermore, there is no established
diabetic animal model to demonstrate all of the vascular and neural
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complications associated with advanced proliferative DR which the study focused
on30. Even though the study mimicked in vitro and in vivo clinical conditions as
closely as possible, the differences should be considered when translating these
types of studies to humans.
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5.3 Future Direction
Clinical reports of DR patients being diagnosed with having glaucoma and
optic neuropathy show that the patients have often undergone PRP laser
treatment multiple years ago. As both glaucoma and the effects of PRP on RNFL
and optic disk are often progressive, it would be enticing to extend the follow up
period beyond 2 years to increase the ability to discern small, yet progressive
changes. The extended study period would potentially allow to determine
predictive factors that affect the progress and rate of the retinal changes.
Regarding the study presented in chapter 3, it is well established that
structural changes precede functional changes. Monitoring patients over 24
month time period might have not been sufficient. To determine whether or not
the effects of anti-VEGF therapy as observed on the RNFL, the optic disk and
ultimately peripheral vision are indeed progressive and cause optic neuropathy, it
would be enticing to extend the follow up period beyond 2 years. The next step
would be to conduct a multi-center study analyzing not just ranibizumab but other
anti-VEGF medications such as bevacizumab and aflibercept. These commonly
used anti-VEGFs all have different molecular characteristics, which cause
differences in potency, systemic clearance, and systemic VEGF inhibition31, 32. It
would be of interest to determine whether higher affinity anti-VEGFs result in
greater changes to the optic nerve as well as if there are any predictive factors
that affect progress and rate of the treatments.
Future studies for chapter 4 should focus on identifying the supporting
cells that became apoptotic under different doses of anti-VEGF. Additionally, the
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study should be repeated using different clinical anti-VEGFs rather than
ranibizumab alone to determine whether higher affinity anti-VEGFs result in
greater amounts of apoptotic cellular death when visualized under
immunofluorescence and with colorimetric assays.
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6

Appendices

6.1 Approved use of human participants undergoing PRP
treatment
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6.2 Approved use of human participants undergoing antiVEGF treatment
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6.3 Approved animal use protocol
>>> eSiriusWebServer <esiriusadmin@uwo.ca> 2015/03/05 4:15 PM >>>

AUP Number: 2010-001
PI Name: Chakrabarti, Subrata
AUP Title: Pathogenesis of Diabetic Retinopathy
Official Notification of AUS Approval: A MODIFICATION to Animal Use Protocol
2010-001 has been approved.
The holder of this Animal Use Protocol is responsible to ensure that all associated
safety components (biosafety, radiation safety, general laboratory safety) comply
with institutional safety standards and have received all necessary approvals. Please
consult directly with your institutional safety officers.
Submitted by: Kinchlea, Will D
on behalf of the Animal Use Subcommittee
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6.4 Copyright permission
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270
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6.5 Antibodies used for experiments

Primary antibody

Dilution

Company, Location

Mouse CD90/Thy
1.1

1:200

Abcam; Toronto, Ont, Canada

Chicken Class III
β-Tubulin
antibody/TUJ-1

1:400

Abcam; Toronto, Ont, Canada

Rabbit Brn3a

1:100

Abcam; Toronto, Ont, Canada

Rabbit cleaved
caspase-3

1:400

Cell Signaling Technology Inc.,
Boston, Massachusetts, USA
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